aspirin has been researched along with Deep Vein Thrombosis in 316 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Excerpt | Relevance | Reference |
---|---|---|
" No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH." | 9.41 | The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023) |
" The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 9.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
"Aspirin at 325 mg twice daily is now included as a nationally approved venous thromboembolism (VTE) prophylaxis protocol for low-risk total knee arthroplasty (TKA) patients." | 9.24 | Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial. ( Gregg, JL; Hussain, LR; Scheuerman, CM; Snyder, MA; Sympson, AN, 2017) |
"This study aimed to compare the efficacy and safety of aspirin, rivaroxaban and low-molecular-weight heparin (LMWH) for post total knee arthroplasty (TKA) deep vein thrombosis (DVT) prophylaxis." | 9.19 | Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. ( Sun, K; Tian, S; Wang, Y; Zou, Y, 2014) |
"Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
"Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 9.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
"To comprehensively evaluate the clinical effects of low molecular weight heparin (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic surgery." | 9.12 | Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. ( Chen, B; Hu, N, 2021) |
"Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain." | 9.12 | Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007) |
"To study the efficacy of daily low-dose aspirin (81 mg orally) in decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T)." | 9.11 | The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005) |
"A prospective, randomized controlled trial was used to compare the efficacy of the arteriovenous (AV) impulse system and aspirin in reducing venous thrombosis after fracture to the femoral neck." | 9.09 | Deep vein thrombosis prophylaxis in hip fractures: a comparison of the arteriovenous impulse system and aspirin. ( Dallo Vedova, PA; Griffen, DR; Kennedy, JG; Kumar, S; Rogers, BW; Sheehan, LJ; Soffe, KE; Sullivan, RJ, 2000) |
"This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days." | 9.09 | Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001) |
"We presented a patient suffered from stroke related to thalidomide therapy." | 8.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
"While there is good evidence for a protective effect of aspirin against occlusive vascular events in individuals with arterial disease, its role in preventing venous thromboembolism (VTE) is unclear." | 8.84 | Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. ( Chee, YL; Watson, HG, 2008) |
"This review summarizes available evidence on effects of aspirin on incidence and outcomes of venous thromboembolism (VTE)." | 8.83 | Aspirin in the prevention and treatment of venous thromboembolism. ( Hovens, MM; Huisman, MV; Snoep, JD; Tamsma, JT, 2006) |
"Although the effect of rectal indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis is well established, the effect of aspirin on acute pancreatitis (AP) is not well studied." | 8.31 | Does use of long-term aspirin impact outcomes in patients with acute pancreatitis? ( Chaudhry, H; Dukovic, D; Kohli, I; Prajapati, D; Sharma, R; Singla, P; Sohal, A; Yang, J, 2023) |
"To evaluate whether a daily full-dose aspirin regimen after anterior cruciate ligament (ACL) reconstruction reduces the risk of postoperative symptomatic deep-venous thrombosis (DVT)." | 8.02 | Aspirin for Deep-Venous Thrombosis Prophylaxis After Anterior Cruciate Ligament Reconstruction. ( Bernstein, EM; Briggs, AM; Ferris, WJ; Hurvitz, AP; McDonald, LS; McIntire, SC; Renninger, CH; Tompane, TM, 2021) |
" However, aspirin (ASA) is routinely used for chemoprophylaxis of deep vein thrombosis (DVT) and is gaining popularity for use after treatment of ankle fractures." | 7.96 | Postoperative aspirin use and its effect on bone healing in the treatment of ankle fractures. ( Anderson, M; Hunter, AM; McGwin, G; Montgomery, TP; Moraes, L; Pitts, CC; Shah, A; Wilson, J, 2020) |
"The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 7.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
" Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0." | 7.96 | Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020) |
"Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 7.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
"ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin." | 7.83 | Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016) |
"Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 6.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
"However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%." | 6.80 | Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015) |
"Symptomatic or asymptomatic deep vein thrombosis (DVT) is a common complication following coronary artery bypass graft (CABG), in which less than 1% of these patients suffer from clinically evident pulmonary embolism (PE)." | 6.78 | Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off-pump coronary artery bypass graft: a randomized clinical trial. ( Ali-Hasan-Al-Saegh, S; Forouzannia, SK; Mirhosseini, SJ; Mostafavi Pour Manshadi, SM; Naderi, N; Sanatkar, M, 2013) |
"Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology." | 6.49 | Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013) |
"In this pilot study, there were no significant differences in any outcome assessed; however, recurrent thromboembolic events and minor bleeding events occurred numerically less frequently in the rivaroxaban plus aspirin group." | 5.69 | Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban. ( Erika, MH; Jaime, GC; Maximiliano, CL, 2023) |
"In patients with extremity fractures that had been treated operatively or with any pelvic or acetabular fracture, thromboprophylaxis with aspirin was noninferior to low-molecular-weight heparin in preventing death and was associated with low incidences of deep-vein thrombosis and pulmonary embolism and low 90-day mortality." | 5.69 | Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture. ( Bosse, MJ; Carlini, AR; Castillo, RC; Degani, Y; Firoozabadi, R; Frey, KP; Goldhaber, SZ; Haut, ER; Marvel, D; O'Hara, NN; O'Toole, RV; Obremskey, W; Scharfstein, DO; Slobogean, GP; Stein, DM; Sudini, K; Taylor, TJ, 2023) |
"Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54." | 5.48 | Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018) |
"Aspirin was associated with a significant protective effect in multivariate analysis, with an odds ratio of 0." | 5.43 | Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective case-control study. ( Bansal, V; Brill, JB; Calvo, RY; Lewis, PR; Shackford, SR; Sise, MJ; Wallace, JD, 2016) |
"The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 5.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
" No significant differences in deep venous thrombosis, pulmonary embolism, and bleeding complications rates were found between aspirin and LMWH." | 5.41 | The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials. ( Gao, S; Liu, W; Meng, J; Tang, H; Wu, Y; Xiao, Y, 2023) |
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke." | 5.33 | Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005) |
" The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy in patients with recent worsening of chronic HF with reduced ejection fraction, coronary artery disease (CAD), and sinus rhythm." | 5.30 | Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial. ( Anker, SD; Byra, WM; Cleland, JGF; Deng, H; Fu, M; Greenberg, B; La Police, DA; Lam, CSP; Mehra, MR; Neaton, JD; Nessel, CC; Spiro, TE; van Veldhuisen, DJ; Vanden Boom, CM; Zannad, F, 2019) |
"Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin." | 5.30 | Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998) |
"Aspirin at 325 mg twice daily is now included as a nationally approved venous thromboembolism (VTE) prophylaxis protocol for low-risk total knee arthroplasty (TKA) patients." | 5.24 | Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial. ( Gregg, JL; Hussain, LR; Scheuerman, CM; Snyder, MA; Sympson, AN, 2017) |
"We conducted a prospective, single-center, active controlled study from July 2013 to January 2015, in Chinese patients with rapid ventricular arrhythmia who had received radiofrequency catheter ablation (RFCA) treatment to determine formation of lower extremity deep vein thrombosis (LDVT) post RFCA procedure, and evaluated the effect of rivaroxaban on LDVT." | 5.22 | Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study. ( Jiang, SB; Li, L; Liu, XZ; Ma, J; Zhang, BJ; Zhang, BK, 2016) |
"This study aimed to compare the efficacy and safety of aspirin, rivaroxaban and low-molecular-weight heparin (LMWH) for post total knee arthroplasty (TKA) deep vein thrombosis (DVT) prophylaxis." | 5.19 | Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty. ( Sun, K; Tian, S; Wang, Y; Zou, Y, 2014) |
"Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
"Aspirin reduced the risk of recurrence when given to patients with unprovoked venous thromboembolism who had discontinued anticoagulant treatment, with no apparent increase in the risk of major bleeding." | 5.16 | Aspirin for preventing the recurrence of venous thromboembolism. ( Ageno, W; Agnelli, G; Becattini, C; Bianchi, M; Bucherini, E; Eichinger, S; Grandone, E; Moia, M; Prandoni, P; Schenone, A; Silingardi, M; Vandelli, MR, 2012) |
"To comprehensively evaluate the clinical effects of low molecular weight heparin (LMWH) and aspirin for deep vein thrombosis (DVT) patients after orthopaedic surgery." | 5.12 | Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis. ( Chen, B; Hu, N, 2021) |
"Deep vein thrombosis prevention efficacy using a new, miniature, mobile, battery-operated pneumatic system (continuous enhanced circulation therapy [CECT] system) combined with low-dose aspirin was compared to enoxaparin." | 5.12 | Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs low molecular weight heparin. ( Gelfer, Y; Halperin, N; Oron, A; Peer, A; Robinson, D; Tavor, H, 2006) |
"Short-term aspirin therapy can lower the risk for venous thromboembolism (VTE) in high-risk patients, but whether the long-term use of low-dose aspirin reduces risk in healthy adults is uncertain." | 5.12 | Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM, 2007) |
"To study the efficacy of daily low-dose aspirin (81 mg orally) in decreasing the incidence of venous thromboembolic events (VTEs) in patients with multiple myeloma receiving pegylated doxorubicin, vincristine, and decreased-frequency dexamethasone, plus thalidomide (DVd-T)." | 5.11 | The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma. ( Andresen, S; Baz, R; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Kottke-Marchant, K; Li, L; McGowan, B; Srkalovic, G; Yiannaki, E; Zeldis, J, 2005) |
"A prospective, randomized controlled trial was used to compare the efficacy of the arteriovenous (AV) impulse system and aspirin in reducing venous thrombosis after fracture to the femoral neck." | 5.09 | Deep vein thrombosis prophylaxis in hip fractures: a comparison of the arteriovenous impulse system and aspirin. ( Dallo Vedova, PA; Griffen, DR; Kennedy, JG; Kumar, S; Rogers, BW; Sheehan, LJ; Soffe, KE; Sullivan, RJ, 2000) |
"This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days." | 5.09 | Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001) |
"Focusing on the current state of the art, this article (a) describes recent advances in the understanding of the pathogenesis of venous thromboembolism (VTE), (b) discusses current approaches for the prevention, diagnosis and treatment of VTE, (c) outlines the role of aspirin for VTE prevention and treatment, and (d) highlights the unmet needs in VTE management and describes novel approaches to address them." | 5.05 | Recent advances in understanding, diagnosing and treating venous thrombosis. ( Chan, NC; Weitz, JI, 2020) |
": Rivaroxaban, a direct oral anticoagulant, is widely used for the treatment of venous thromboembolism (VTE) in adult patients." | 5.01 | Rivaroxaban and the EINSTEIN clinical trial programme. ( Bauersachs, R; Cohen, AT, 2019) |
"Aspirin, both alone and in multimodal approaches to thromboprophylaxis, confers a low rate of VTE, with a low risk of major bleeding complications." | 4.93 | Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( An, VV; Bruce, WJ; Levy, YD; Phan, K, 2016) |
" first venous thrombosis) should be treated with warfarin to an INR 2." | 4.85 | Management of antiphospholipid syndrome. ( Khamashta, MA; Tuthill, JI, 2009) |
"Lenalidomide, an analog of thalidomide, is an effective new treatment for multiple myeloma." | 4.84 | Risk of thrombosis with lenalidomide and its prevention with aspirin. ( Hirsh, J, 2007) |
" The relationship between low-dose aspirin and bleeding was explored by incidence rates and rates per 100 person-years." | 4.84 | Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. ( Bergsland, E; Gerber, HP; Holden, SN; Holmgren, E; Hurwitz, H; Kabbinavar, F; Miller, K; Ngai, J; Scappaticci, FA; Skillings, JR; Wang, J, 2007) |
"We presented a patient suffered from stroke related to thalidomide therapy." | 4.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
"While there is good evidence for a protective effect of aspirin against occlusive vascular events in individuals with arterial disease, its role in preventing venous thromboembolism (VTE) is unclear." | 4.84 | Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism. ( Chee, YL; Watson, HG, 2008) |
"This review summarizes available evidence on effects of aspirin on incidence and outcomes of venous thromboembolism (VTE)." | 4.83 | Aspirin in the prevention and treatment of venous thromboembolism. ( Hovens, MM; Huisman, MV; Snoep, JD; Tamsma, JT, 2006) |
"Based on the established fact that anticoagulation with warfarin is superior to antiplatelet agents in the prevention of thromboembolic events in atrial fibrillation (AF), we propose that, in contrast to atherothrombotic disorders, the risk of developing a stroke or thromboembolic event in AF is more likely to be affected by the coagulation pathway than by platelet activity." | 4.82 | Atrial fibrillation: should we target platelets or the coagulation pathway? ( Lip, GY; Tan, KT, 2003) |
"Anticoagulant therapy is indicated during pregnancy for the prevention and treatment of VTE; for the prevention and treatment of systemic embolism in patients with mechanical heart valves; and, often in combination with aspirin, for the prevention of pregnancy loss in women with APLAs or thrombophilia and previous pregnancy losses." | 4.81 | Use of antithrombotic agents during pregnancy. ( Ginsberg, JS; Greer, I; Hirsh, J, 2001) |
" The purpose of this study was to define the efficacy and safety of the agents that are currently used for prophylaxis against deep venous thrombosis -- namely, low-molecular-weight heparin, warfarin, aspirin, low-dose heparin, and pneumatic compression." | 4.80 | A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. ( Brookenthal, KR; Fitzgerald, RH; Freedman, KB; Lonner, JH; Williams, S, 2000) |
"Although the effect of rectal indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis is well established, the effect of aspirin on acute pancreatitis (AP) is not well studied." | 4.31 | Does use of long-term aspirin impact outcomes in patients with acute pancreatitis? ( Chaudhry, H; Dukovic, D; Kohli, I; Prajapati, D; Sharma, R; Singla, P; Sohal, A; Yang, J, 2023) |
" The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin." | 4.12 | Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022) |
" Case presentation A 66-year-old Japanese male patient received regorafenib for metastatic colorectal carcinoma and apixaban for deep vein thrombosis." | 4.02 | Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report. ( Matoba, S; Ookura, T; Shoji, K; Yanishi, K; Zen, K, 2021) |
"To evaluate whether a daily full-dose aspirin regimen after anterior cruciate ligament (ACL) reconstruction reduces the risk of postoperative symptomatic deep-venous thrombosis (DVT)." | 4.02 | Aspirin for Deep-Venous Thrombosis Prophylaxis After Anterior Cruciate Ligament Reconstruction. ( Bernstein, EM; Briggs, AM; Ferris, WJ; Hurvitz, AP; McDonald, LS; McIntire, SC; Renninger, CH; Tompane, TM, 2021) |
" However, aspirin (ASA) is routinely used for chemoprophylaxis of deep vein thrombosis (DVT) and is gaining popularity for use after treatment of ankle fractures." | 3.96 | Postoperative aspirin use and its effect on bone healing in the treatment of ankle fractures. ( Anderson, M; Hunter, AM; McGwin, G; Montgomery, TP; Moraes, L; Pitts, CC; Shah, A; Wilson, J, 2020) |
"The purpose of this meta-analysis is to compare the efficacy and safety of aspirin and rivaroxaban in the prevention of venous thromboembolism (VTE) following either total knee arthroplasty or total hip arthroplasty." | 3.96 | Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis. ( Le, G; Luo, H; Tang, J; Xi, L; Yang, C; Zhang, M; Zhao, J, 2020) |
" Aspirin has been considered a safe and cost-effective prophylaxis for venous thromboembolism (VTE), and there have been some reports about the incidence of PTE (0%-0." | 3.96 | Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty. ( Hirakawa, K; Mihara, M; Nakura, N; Ochiai, S; Saito, A; Takayanagi, S; Tamaki, Y, 2020) |
"The results of this study clearly show that aspirin, as part of a multimodal thromboprophylactic regime, is an effective and safe regime in preventing venous thromboembolism with respect to risk of deep vein thrombosis or pulmonary embolism when compared to LMWH." | 3.91 | Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases. ( Best, AJ; Chatterji, U; Ghosh, A; Rudge, SJ, 2019) |
"The aims of this study were to compare the efficacy of two agents, aspirin and warfarin, for the prevention of venous thromboembolism (VTE) after simultaneous bilateral total knee arthroplasty (SBTKA), and to elucidate the risk of VTE conferred by this procedure compared with unilateral TKA (UTKA)." | 3.88 | Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin ( Fleischman, AN; Goel, R; Higuera, C; Huang, R; Parvizi, J; Rothman, RH; Sterbis, E; Tan, T, 2018) |
"Aspirin and unfractionated heparin (UH) are accepted options for venous thromboembolism (VTE) prophylaxis after total joint arthroplasty (TJA)." | 3.88 | The Role of Aspirin and Unfractionated Heparin Combination Therapy Immediately After Total Hip and Knee Arthroplasty. ( Karadsheh, MS; Koueiter, DM; Mells, A; Siljander, MP; Sobh, AH, 2018) |
"Aspirin is an effective prophylaxis for venous thromboembolism (VTE) after total knee arthroplasty (TKA)." | 3.88 | Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty. ( Barsoum, WK; Brigati, DP; Faour, M; Higuera, CA; Klika, AK; Mont, MA; Piuzzi, NS, 2018) |
"There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
"ESSENTIALS: We audited venous thromboembolism (VTE) in Achilles injuries after the use of prophylactic aspirin." | 3.83 | Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit. ( Beasley, R; Braithwaite, I; Dunbar, L; Eathorne, A; Weatherall, M, 2016) |
"This study's purpose was to present our institution's experience with the use of a risk stratification protocol for venous thromboembolism (VTE) prophylaxis in joint arthroplasty in which "routine" risk patients receive a mobile compression device in conjunction with aspirin and "high"-risk patients receive warfarin for thromboprophylaxis." | 3.83 | The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty. ( Barrack, RL; Clohisy, JC; Johnson, SR; Keeney, JA; Nam, D; Nunley, RM, 2016) |
"01) the rate of transfusion, units of packed red blood cells, hemoglobin drop, and hematocrit drop compared to aspirin in both unilateral and bilateral TKA patients, without significantly decreasing venous thromboembolism events (aspirin: 3 pulmonary embolisms and 4 deep venous thrombosis; Lovenox: 3 pulmonary embolisms and 2 deep venous thrombosis)." | 3.83 | Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. ( Hall, KE; Nakasone, CK; Radzak, KN; Wages, JJ, 2016) |
"We sought to determine the frequency of thromboembolic events (deep vein thrombosis [DVT] and symptomatic pulmonary embolism [PE]) associated with the periacetabular osteotomy in in patients receiving aspirin and mechanical compression prophylaxis." | 3.80 | Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary? ( Bloemke, AD; Clohisy, JC; Duncan, ST; Polkowski, GG; Schoenecker, PL, 2014) |
" Geniposide and genipin were studied on venous thrombosis by oral administration." | 3.79 | Antithrombotic activities of aqueous extract from Gardenia jasminoides and its main constituent. ( Liu, H; Wei, SF; Yang, M; Zhang, HY, 2013) |
"Our institution has used a thromboprophylaxis regimen consisting of inpatient enoxaparin and outpatient aspirin for patients at standard risk for venous thrombosis after hip and knee arthroplasty." | 3.78 | Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. ( Anderson, BJ; Bradbury, TL; Erens, GA; Hamilton, SC; Roberson, JR; Whang, WW, 2012) |
"It is safe to continue low-dose (100 mg/day) aspirin in the perioperative period as a part of multimodal prophylaxis against deep vein thrombosis." | 3.78 | Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. ( Cossetto, DJ; Goudar, A; Parkinson, K, 2012) |
"To compare venous thrombosis rates among animals treated with aspirin, clopidogrel bisulfate, and ketorolac tromethamine using an anastomotic "tuck" model." | 3.77 | Effects of antithrombogenic agents on microvenous anastomoses in a rat model. ( Harsha, WJ; Hayden, RE; Kau, RL; Kim, N, 2011) |
" Deep vein thrombosis prophylaxis consisted of oral enteric-coated aspirin, pneumatic calf compression pumps, and early ambulation in all patients unless medically contraindicated." | 3.77 | Thromboembolic events are uncommon after open treatment of proximal humerus fractures using aspirin and compression devices. ( Abboud, JA; Bassora, R; Warrender, WJ; Widmer, BJ, 2011) |
"Our objective of the study was to address the question: "What is the efficacy of a deep venous thrombosis (DVT) and pulmonary embolus prophylaxis protocol after total knee arthroplasty (TKA) in which low-risk patients had only aspirin and mechanical devices for prophylaxis?" A multimodal approach to DVT prophylaxis using aspirin as the primary mode of chemoprophylaxis was successful in preventing DVT-related morbidity and mortality in 312 consecutive TKAs performed in low-risk patients." | 3.74 | Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. ( Callaghan, JJ; Hoballah, JJ; Liu, SS; Warth, LC; Wells, CW, 2008) |
" Patients who received low-molecular-weight heparin for prophylaxis against deep venous thrombosis had a longer time until the postoperative wound was dry than did those treated with aspirin and mechanical foot compression or those who received Coumadin (warfarin); this difference was significant on the fifth postoperative day (p = 0." | 3.74 | Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty. ( DeWal, H; Di Cesare, PE; Patel, VP; Preston, C; Sehgal, B; Walsh, M, 2007) |
"Deep vein thrombosis (DVT) remains common in patients with acute ischemic stroke (AIS) receiving aspirin and graded compression stockings (considered standard thromboprophylaxis in the UK), most events occurring in patients with Barthel indices (BI) of <9 ('severe stroke') around the time of admission." | 3.72 | Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Parmar, K; Rudd, A, 2004) |
"One hundred ninety-nine patients who underwent primary total hip arthroplasty and used in hospital pneumatic compression stockings and aspirin as thromboembolic prophylaxis were screened for deep venous thrombosis using duplex ultrasonography on the fourth postoperative day." | 3.70 | Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty. ( Buehler, KO; Colwell, CW; D'Lima, DD; Petersilge, WJ; Walker, RH, 1999) |
" Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
"This retrospective study was performed to examine the influence of aspirin on the incidence of RVT in cadaveric and living-related renal transplant recipients receiving cyclosporin-based triple immunosuppression." | 3.70 | Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients. ( Gray, DW; Morris, PJ; Nargund, V; Robertson, AJ, 2000) |
"Warfarin treatment was associated with better liver function protection and renal function improvement than aspirin treatment." | 2.90 | Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: A randomized clinical trial. ( Bai, DS; Jiang, GQ; Jin, SJ; Qian, JJ; Xia, BL; Ye, J; Zhang, C, 2019) |
"Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 2.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
" GI bleeding was equally prevalent between the 2 dosing regimens, so patients need to be informed of this risk regardless of the ASA dose." | 2.84 | A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties. ( Chen, AF; Feldstein, MJ; Hozack, WJ; Low, SL; Woodward, LA, 2017) |
"However, more recently, the rate of deep vein thrombosis (DVT) has been reported to be approximately 10%." | 2.80 | Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial. ( Alaia, MJ; Garofolo, G; Jazrawi, LM; Kaye, ID; Martinez, A; Patel, DN; Strauss, EJ, 2015) |
"Symptomatic or asymptomatic deep vein thrombosis (DVT) is a common complication following coronary artery bypass graft (CABG), in which less than 1% of these patients suffer from clinically evident pulmonary embolism (PE)." | 2.78 | Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off-pump coronary artery bypass graft: a randomized clinical trial. ( Ali-Hasan-Al-Saegh, S; Forouzannia, SK; Mirhosseini, SJ; Mostafavi Pour Manshadi, SM; Naderi, N; Sanatkar, M, 2013) |
"Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VTE (no recent surgery, trauma, or cancer diagnosis) were prospectively evaluated, secondary end points of the trial." | 2.73 | Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study. ( Buring, JE; Glynn, RJ; Goldhaber, SZ; Ridker, PM; Zee, RY, 2007) |
"Aspirin was started on the day of surgery, whereas enoxaparin was started 48 hours after surgery." | 2.72 | VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. ( Bottner, F; Haas, SB; Laskin, RS; Sculco, TP; Westrich, GH; Windsor, RE, 2006) |
"The incidence of pulmonary embolism (PE) in all trials combined was low, with seven cases in 3818 participants." | 2.66 | Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy. ( Badariotti, G; Chahla, J; Perrotta, C; Ramos, J, 2020) |
"Venous thromboembolic disease (VTED) (deep venous thrombosis and pulmonary embolism) is a considerable source of morbidity and mortality following lower extremity total joint arthroplasty." | 2.52 | What's New in Venous Thromboembolic Prophylaxis Following Total Knee and Total Hip Arthroplasty? An Update. ( Cherian, JJ; Elmallah, RK; Jauregui, JJ; Mont, MA; Pierce, TP, 2015) |
"Is it better to continue treatment of deep venous thrombosis or pulmonary embolism with LMWH or switch to an oral anticoagulant? What is the optimal duration of treatment? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology." | 2.49 | Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months. ( , 2013) |
"Keywords used were DVT, thromboembolism, deep vein thrombosis and air travel-related venous thromboembolism." | 2.47 | All I want for coagulation. ( Bridgett, MR; Nunn, KP; Walker, I; Walters, MR, 2011) |
"Deep Venous Thrombosis is a common disease with fatal and serious long term burdensome complications." | 2.45 | Deep vein thrombosis: risk factors and prevention in surgical patients. ( Adekoya-Cole, TO; Enweluzo, GO; Giwa, SO; Obalum, DC; Ogo, CN, 2009) |
"Ten patients with aneurysms and/or pseudoaneurysms and six patients with occlusive lesions have undergone surgical treatment." | 2.44 | Major arterial involvement and review of Behcet's disease. ( Alpagut, U; Dayioglu, E; Ugurlucan, M, 2007) |
"Fatal pulmonary embolism is estimated to occur in nearly 1% of these women." | 2.44 | WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2007) |
" The oral immunomodulatory drugs thalidomide and lenalidomide have produced major therapeutic responses in patients with MM when used in combination with oral steroids and chemotherapy, but a high incidence of VTE has been reported." | 2.43 | Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. ( Hussein, MA, 2006) |
"Venous thromboembolism is a common complication following a hip replacement." | 2.42 | Thromboprophylaxis in patients undergoing total hip replacement. ( Brenkel, IJ; Cook, RE, 2003) |
"Many authors relate this factor with preeclampsia, intrauterine fetal growth retardation, spontaneous abortion, unexplained cases of still birth, placental abruption, and thromboembolic complications during and after parturition." | 2.42 | [Factor V Leiden mutation and pregnancy complications]. ( Abraitis, V; Mockeviciene, A; Mongirdiene, A, 2003) |
"Fatal pulmonary embolism is estimated to occur in nearly 1% of these women." | 2.42 | Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery. ( D'Angelo, A; Mol, B; Oates-Whitehead, RM, 2003) |
"Venous thromboembolism is a frequent and serious disorder influenced by numerous factors." | 2.42 | Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. ( Dahl, OE; Mismetti, P; Quinlan, DJ; Rosencher, N; Samama, MM, 2003) |
" Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) do not cross the placenta and are safe for the fetus, but long-term treatment with UFH is problematic because of its inconvenient administration, the need to monitor anticoagulant activity and because of its potential side effects, such as heparin-induced thrombocytopenia and osteoporosis." | 2.42 | The safety of antithrombotic therapy during pregnancy. ( Ageno, W; Crotti, S; Turpie, AG, 2004) |
"Aspirin has also demonstrated a potential ability to reduce the risk of deep venous thrombosis and pulmonary embolism." | 2.41 | An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I. ( Moyad, MA, 2001) |
"Thrombosis is of greater overall clinical importance in terms of morbidity and mortality than all of the hemorrhagic disorders combined." | 2.41 | Antithrombotic agents: implications in dentistry. ( Henry, RG; Little, JW; McIntosh, BA; Miller, CS, 2002) |
"Aspirin was first synthesised 100 years ago and its preparation and marketing is generally reckoned to have been the foundation of the pharmaceutical industry." | 2.40 | Platelets, aspirin, and cardiovascular disease. ( Elwood, PC; Hughes, C; O'Brien, JR, 1998) |
"After the procedure, deep vein thrombosis (DVT) was a commonly diagnosed complication (3." | 1.91 | Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention. ( Agala, C; Caruso, DM; Duchesneau, E; Farber, M; Kindell, DG; Marston, WA; Marulanda, K; McGinigle, KL, 2023) |
"The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations." | 1.91 | Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023) |
"Similarly, thrombus weights were reduced in mice with impaired ITAM signaling (Clec2mKO + JAQ1; WT + ibrutinib) but not in Clec2mKO or WT + JAQ1 mice." | 1.72 | Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice. ( Bergmeier, W; Cooley, BC; Holle, LA; Kawano, T; Lee, RH; Mackman, N; Mwiza, JMN; Nieswandt, B; Paul, DS; Schug, WJ; Wolberg, AS, 2022) |
"The current rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) at our institution following hip or knee arthroplasty or hip fracture surgery are 1." | 1.56 | Incidence of venous thromboembolism after total hip, total knee and hip fracture surgery at Waitemata District Health Board following a peer-reviewed audit. ( Andrew, P; Farrington, B; Lawes, CM; Merriman, E; Millar, JS; Misur, P; Walker, M, 2020) |
"Incidence of postoperative deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding-related complications, postoperative anaemia, and transfusion were identified at 2 weeks, 30 days, 6 weeks, and 90 days." | 1.56 | Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? ( Amanatullah, DF; Bala, A; Burk, DR; Goodman, SB; Huddleston, JI; Maloney, WJ; Murasko, MJ, 2020) |
"Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained." | 1.51 | Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019) |
"We report a patient who had recurrent deep vein thrombosis (DVT) as the presenting symptom of Behcet's Disease." | 1.48 | Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease. ( Chun, K; Lakha, S; Png, CYM; Ting, W, 2018) |
"No thrombosis was detected." | 1.48 | Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol® supplementation (LONFLIT Registry Study). ( Belcaro, G; Cornelli, U; Cotellese, R; Dugall, M; Feragalli, B; Hosoi, M, 2018) |
"Imaging revealed an acute cerebral venous thrombosis." | 1.48 | CO poisoning as an associated risk factor for CVT. ( Gibb, GJ; Laghari, FJ; Phinney, TA, 2018) |
"Deep venous thrombosis is one of the common complications after major surgery in the Department of Orthopedics." | 1.48 | Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation. ( Nie, L; Xu, W; Yang, Z; Zhang, T, 2018) |
"Warfarin treatment within 12 months achieved significantly higher rates of complete recanalization than aspirin or clopidogrel in patients with PVT (54." | 1.48 | Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes. ( Li, YH; Wu, HM; Xu, Y; Yang, J; Yang, LH; Yue-Meng, W, 2018) |
"EHIT can lead to deep vein thrombosis/pulmonary embolism, which cause significant disability and, rarely, death." | 1.46 | Outcomes of a single-center experience with classification and treatment of endothermal heat-induced thrombosis after endovenous ablation. ( Chambers, CM; Cuff, RF; Korepta, LM; Mansour, MA; Slaikeu, JD; Watson, JJ; Wong, PY, 2017) |
"Aspirin was associated with a significant protective effect in multivariate analysis, with an odds ratio of 0." | 1.43 | Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective case-control study. ( Bansal, V; Brill, JB; Calvo, RY; Lewis, PR; Shackford, SR; Sise, MJ; Wallace, JD, 2016) |
"Multiple myeloma is a malignant plasma cells dyscrasia that mainly affects patients older than 65 years." | 1.43 | [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?]. ( Carrier, M; de Moreuil, C; Delluc, A; Eveillard, JR; Ianotto, JC, 2016) |
"The incidence of symptomatic deep vein thrombosis and pulmonary embolism was evaluated." | 1.43 | Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis. ( Chen, AF; Heller, S; Parvizi, J; Secrist, E; Shahi, A, 2016) |
"The rate of surgical site infection was similar between the aspirin group and the warfarin group (1." | 1.43 | Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty. ( Chen, AF; Deirmengian, GK; Heller, S; Maltenfort, M; Parvizi, J; Smith, EB, 2016) |
"Most of the children (88." | 1.42 | Case series of thromboembolic complications in childhood nephrotic syndrome: Hacettepe experience. ( Aytac, S; Besbas, N; Cetin, M; Gumruk, F; Kara, F; Kuskonmaz, B; Tavil, B; Topaloglu, R; Unal, S, 2015) |
"Incidences of symptomatic deep vein thrombosis (DVT) and PE, and major or minor bleeding complications were evaluated." | 1.42 | Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients. ( Cho, KJ; Fang, R; Kim, TK; Kim, YH; Na, YG, 2015) |
"Thulium VapoEnucleation of the prostate seems to be a safe and efficacious procedure for the treatment of symptomatic BPO in patients at high cardiopulmonary risk on OA." | 1.40 | Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy. ( Bach, T; Brüning, M; Gabuev, A; Gross, AJ; Herrmann, TR; Netsch, C; Stoehrer, M, 2014) |
"Cerebral venous thrombosis is a rare condition with various clinical presentations which may delay diagnosis." | 1.40 | Thrombosis of the great cerebral vein in a hemodialysis patient. ( Basic-Jukic, N; Gledovic, B; Radunovic, D; Ratkovic, M, 2014) |
"Lenalidomide has significant antimyeloma activity but it is associated with a significant risk of venous thromboembolism (VTE)." | 1.39 | Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. ( Bagratuni, T; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Gavriatopoulou, M; Kanelias, N; Kastritis, E; Kostouros, E; Politou, M; Roussou, M; Terpos, E, 2013) |
"270 patients (93 with deep vein thrombosis (DVT) or pulmonary embolism (PE), and 177 with non-haemorrhagic stroke (cerebrovascular accident (CVA)) admitted between January 2006 and December 2010 with a discharge diagnosis of either DVT, PE or CVA, who had LAC and antiphospholipid antibodies measured within 6 months from their index admission." | 1.38 | High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study. ( Broder, A; Putterman, C; Tobin, JN, 2012) |
"Case 2: Three-yr-old boy with IgA deficiency and liver disease." | 1.38 | Budd-Chiari syndrome in children and outcome after liver transplant. ( Cipriano, A; Furtado, E; Gomes, AC; Gonçalves, I; Pinto, C; Rubino, G, 2012) |
"The rate of VTE, pulmonary embolism, proximal deep vein thrombosis (DVT) and distal DVT was 1." | 1.38 | Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol. ( Esposito, A; Gesell, M; Gonzalez Della Valle, A; Ma, Y; Memtsoudis, SG; Vulcano, E, 2012) |
"Incidence of postoperative hemorrhage (early and delayed) was not significant (P = ." | 1.37 | Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications. ( Bariol, SV; Brooks, AJ; Drummond, M; Lau, HM; McDonald, C; Patel, MI; Raj, MD; Wang, AC; Woo, HH, 2011) |
"Diabetes mellitus is associated with platelet hyperactivity, which leads to increased morbidity and mortality from cardiovascular disease." | 1.37 | Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. ( Capone, M; Di Febbo, C; Evangelista, V; Fava, C; Gleim, S; Hwa, J; Levantesi, G; Martin, K; Minuz, P; Patrignani, P; Porreca, E; Rade, J; Stitham, J; Tacconelli, S; Tang, WH; Wen, L, 2011) |
"To determine prevalence of central vein stenosis following catheterization with double-lumen temporary catheters, we performed color Doppler sonography in 100 consecutive patients." | 1.36 | Prevalence of central vein stenosis following catheterization in patients with end-stage renal disease. ( Naroienejad, M; Rezvani, A; Saedi, D, 2010) |
" Dosing of IV UFH should prolong the activated partial thromboplastin time (aPTT) to a range that corresponds to an anti-factor Xa assay (anti-FXa) level of 0." | 1.35 | Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Chalmers, E; Chan, A; deVeber, G; Kirkham, F; Massicotte, P; Michelson, AD; Monagle, P, 2008) |
"Deep venous thrombosis (DVT) and pulmonary embolism (PE) cause significant morbidity and mortality in orthopaedic surgical practice, although the incidence following surgery to the lumbosacral spine is less than following lower limb surgery." | 1.35 | Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients. ( Craig, N; Nicol, M; Sun, Y; Wardlaw, D, 2009) |
"Local thrombolysis of deep vein thrombosis with ultrasound surveillance is, in indicated patients, a safe method even if a vein injury occurs." | 1.35 | [Repeated local thrombolysis in a patient with axillary and subclavian vein injury and thrombosis]. ( Hofírek, I; Sárník, S, 2009) |
"The classical clinical picture of antiphospholipid antibody syndrome (APS) is characterized by venous and arterial thrombosis, fetal losses and thrombocytopenia in the presence of anticardiolipin antibodies and/or lupus anticoagulant." | 1.35 | Paediatric case report: primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone? ( Alhumayed, S; Alshehri, A; Shabana, M; Shalaby, M, 2009) |
"Twenty patients in each group had deep venous thrombosis (7% and 5." | 1.34 | Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol. ( Anderson, J; Beksaç, B; González Della Valle, A; Salvato, EA; Sculco, TP; Sharrock, NE, 2007) |
"Clinically symptomatic deep venous thrombosis was detected in association with four (0." | 1.34 | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007) |
"Nonfatal pulmonary embolisms were diagnosed in 17 (0." | 1.33 | Thromboembolic disease prophylaxis in total hip arthroplasty. ( Goswami, A; Sarmiento, A, 2005) |
"(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke." | 1.33 | Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005) |
"Antiphospholipid syndrome is a recognized disorder of pregnancy." | 1.33 | Maternal and fetal complications of antiphospholipid syndrome: a case report with long-term follow-up. ( Khurshid, M; Naru, T; Nazir, Z, 2006) |
"As the problem of morbid obesity has increased over the past several years in the United States, gastric bypass has become a viable option for many people seeking treatment." | 1.33 | Preventing vascular complications after gastric bypass. ( Heffline, MS, 2006) |
"Data indicate that deep venous thrombosis (DVT) occurs at the time of knee arthroplasty." | 1.32 | A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty. ( Emerson, RH; Higgins, LL; Reitman, RD; Tarbox, TR, 2003) |
"Early administration of a combined regimen of clopidogrel and aspirin following off-pump CABG is safe and is associated with a relatively low incidence of major adverse cardiac events, bleeding, PE, and DVT." | 1.32 | A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting. ( Benhameid, O; Endo, M; Shennib, H, 2003) |
"Protein C and protein S deficiency were found in nine and two patients, respectively." | 1.32 | Venous thrombosis among patients with AIDS. ( Corona-de la Peña, N; de Chávez-Ochoa, AR; Majluf-Cruz, A; Montiel-Manzano, G; Nieto-Cisneros, L; Sánchez-Barboza, R; Santoscoy-Gómez, M; Silva-Estrada, M; Treviño-Pérez, S, 2004) |
"Treatment with aspirin+heparin alone reduced thrombus weight by 37+/-25% (18." | 1.32 | Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study. ( Atar, S; Birnbaum, Y; Horzewski, M; Kaul, S; Kobal, S; Luo, H; Miyamoto, T; Neuman, Y; Rukshin, V; Siegel, RJ; Thompson, T; Tsang, V, 2003) |
"The prevalence of all VTE, proximal deep vein thrombosis (PDVT), and pulmonary embolism (PE) after 21 days were 40%, 18%, and 12%, increasing to 63%, 30%, and 20% in patients with Barthel indices (BI) of < or =9 2 days after stroke (BI-2< or =9)." | 1.32 | Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging. ( Coshall, C; Hunt, BJ; Kelly, J; Lewis, RR; Moody, A; Rudd, A, 2004) |
"Two (2." | 1.31 | Isolated internal jugular vein thrombosis: risk factors and natural history. ( Deitcher, SR; Sheikh, MA; Topoulos, AP, 2002) |
"Thirty-nine patients with deep vein thrombosis, 28 with arteriosclerosis obliterans, and 10 with pulmonary embolism were the subjects of this study." | 1.31 | Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy. ( Morimoto, Y; Mukai, T; Okada, M; Sugimoto, T, 2000) |
"Patients with antiphospholipid antibody syndrome (APS) have a high risk for rethrombosis." | 1.31 | Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis. ( Brunner, HI; Chan, WS; Feldman, BM; Ginsberg, JS, 2002) |
"Venous thrombosis was reduced 56% by oral soluble acetylsalicylic acid and 27% by oral aspirin." | 1.30 | Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal. ( Iomhair, MM; Lavelle, SM, 1998) |
"Deep venous thrombosis was diagnosed after seven procedures (0." | 1.30 | Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty. ( Goswami, AD; Sarmiento, A, 1999) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 10 (3.16) | 18.2507 |
2000's | 162 (51.27) | 29.6817 |
2010's | 113 (35.76) | 24.3611 |
2020's | 31 (9.81) | 2.80 |
Authors | Studies |
---|---|
Batra, S | 1 |
Srinivasan, T | 1 |
Rastogi, SK | 1 |
Kundu, B | 1 |
Patra, A | 1 |
Bhaduri, AP | 1 |
Dixit, M | 1 |
Hou, M | 1 |
Lv, M | 2 |
Zhang, X | 1 |
Wang, Y | 2 |
Zhao, S | 1 |
Wu, J | 1 |
Peng, S | 1 |
Zhao, M | 1 |
Kirchner, VA | 1 |
O'Farrell, B | 1 |
Imber, C | 1 |
McCormack, L | 1 |
Northup, PG | 1 |
Song, GW | 1 |
Spiro, M | 1 |
Raptis, DA | 1 |
Durand, F | 1 |
Mwiza, JMN | 1 |
Lee, RH | 1 |
Paul, DS | 1 |
Holle, LA | 1 |
Cooley, BC | 1 |
Nieswandt, B | 1 |
Schug, WJ | 1 |
Kawano, T | 1 |
Mackman, N | 1 |
Wolberg, AS | 1 |
Bergmeier, W | 1 |
Li, Y | 2 |
Fu, X | 1 |
Liu, P | 1 |
Liu, S | 1 |
Pan, Y | 1 |
Metcalf, KB | 1 |
Du, JY | 1 |
Ochenjele, G | 1 |
Pires da Rosa, G | 1 |
Ferreira, E | 1 |
Sousa-Pinto, B | 1 |
Rodríguez-Pintó, I | 1 |
Brito, I | 1 |
Mota, A | 1 |
Cervera, R | 2 |
Espinosa, G | 2 |
Kindell, DG | 1 |
Marulanda, K | 1 |
Caruso, DM | 1 |
Duchesneau, E | 1 |
Agala, C | 1 |
Farber, M | 1 |
Marston, WA | 1 |
McGinigle, KL | 1 |
Engler, ID | 3 |
Maximiliano, CL | 1 |
Jaime, GC | 1 |
Erika, MH | 1 |
O'Toole, RV | 1 |
Stein, DM | 1 |
O'Hara, NN | 1 |
Frey, KP | 1 |
Taylor, TJ | 1 |
Scharfstein, DO | 1 |
Carlini, AR | 1 |
Sudini, K | 1 |
Degani, Y | 1 |
Slobogean, GP | 1 |
Haut, ER | 1 |
Obremskey, W | 1 |
Firoozabadi, R | 1 |
Bosse, MJ | 1 |
Goldhaber, SZ | 3 |
Marvel, D | 1 |
Castillo, RC | 1 |
Agarwal, AR | 1 |
Das, A | 1 |
Harris, A | 1 |
Campbell, JC | 1 |
Golladay, GJ | 1 |
Thakkar, SC | 1 |
Rosenberg, K | 1 |
Chaudhry, H | 1 |
Sohal, A | 1 |
Dukovic, D | 1 |
Kohli, I | 1 |
Sharma, R | 1 |
Singla, P | 1 |
Prajapati, D | 1 |
Yang, J | 2 |
Poacher, AT | 1 |
Hoskins, HC | 1 |
Protty, MB | 1 |
Pettit, R | 1 |
Johansen, A | 1 |
Tsai, SW | 1 |
Chang, WL | 1 |
Pai, FY | 1 |
Chou, TA | 1 |
Chen, CF | 1 |
Wu, PK | 1 |
Chen, WM | 1 |
Meng, J | 1 |
Liu, W | 1 |
Xiao, Y | 1 |
Tang, H | 1 |
Wu, Y | 1 |
Gao, S | 1 |
Liu, HZ | 1 |
Liang, J | 1 |
Hu, AX | 1 |
Du, ZQ | 1 |
Zhao, JZ | 1 |
Dong, J | 1 |
Bi, JB | 1 |
Ren, YF | 1 |
Zhang, J | 1 |
Khalid, B | 1 |
Wu, Z | 1 |
Lv, Y | 1 |
Zhang, XF | 1 |
Wu, RQ | 1 |
Jastifer, J | 1 |
Manson, W | 1 |
Smith, B | 1 |
Cooper, MT | 1 |
Brigido, SA | 1 |
Hunter, AM | 1 |
Montgomery, TP | 1 |
Pitts, CC | 1 |
Moraes, L | 1 |
Anderson, M | 1 |
Wilson, J | 1 |
McGwin, G | 1 |
Shah, A | 1 |
Millar, JS | 1 |
Lawes, CM | 1 |
Farrington, B | 1 |
Andrew, P | 1 |
Misur, P | 1 |
Merriman, E | 1 |
Walker, M | 1 |
Perrotta, C | 1 |
Chahla, J | 1 |
Badariotti, G | 1 |
Ramos, J | 1 |
Lal, S | 1 |
Hashmi, J | 1 |
Chan, NC | 2 |
Weitz, JI | 2 |
Le, G | 1 |
Yang, C | 1 |
Zhang, M | 1 |
Xi, L | 1 |
Luo, H | 2 |
Tang, J | 1 |
Zhao, J | 1 |
Gangat, N | 1 |
Tefferi, A | 1 |
Hughes, LD | 1 |
Lum, J | 1 |
Mahfoud, Z | 1 |
Malik, RA | 1 |
Anand, A | 1 |
Charalambous, CP | 1 |
Chen, B | 1 |
Hu, N | 1 |
Shoji, K | 1 |
Zen, K | 1 |
Ookura, T | 1 |
Yanishi, K | 1 |
Matoba, S | 1 |
McIntire, SC | 1 |
Bernstein, EM | 1 |
Tompane, TM | 1 |
Briggs, AM | 1 |
Ferris, WJ | 1 |
Renninger, CH | 1 |
McDonald, LS | 1 |
Hurvitz, AP | 1 |
Bravo-Perez, C | 1 |
Fernández-Caballero, M | 1 |
Soler-Espejo, E | 1 |
Garcia-Torralba, E | 1 |
Sorigue, M | 1 |
García-Malo, MD | 1 |
Jerez, A | 1 |
Vicente, V | 1 |
Roldán, V | 1 |
de Arriba, F | 1 |
Korepta, LM | 1 |
Watson, JJ | 1 |
Mansour, MA | 1 |
Chambers, CM | 1 |
Cuff, RF | 1 |
Slaikeu, JD | 1 |
Wong, PY | 1 |
Snyder, MA | 2 |
Sympson, AN | 2 |
Zan, P | 1 |
Li, G | 1 |
Bala, A | 2 |
Huddleston, JI | 2 |
Goodman, SB | 2 |
Maloney, WJ | 2 |
Amanatullah, DF | 2 |
Cafri, G | 1 |
Paxton, EW | 1 |
Chen, Y | 1 |
Cheetham, CT | 1 |
Gould, MK | 1 |
Sluggett, J | 1 |
Bini, SA | 1 |
Khatod, M | 1 |
Gupta, E | 1 |
Siddiqi, FS | 1 |
Kunjal, R | 1 |
Faisal, M | 1 |
Al-Saffar, F | 1 |
Bajwa, AA | 1 |
Jones, LM | 1 |
Seeram, V | 1 |
Cury, JD | 1 |
Shujaat, A | 1 |
Jones, CW | 1 |
Spasojevic, S | 1 |
Goh, G | 1 |
Joseph, Z | 1 |
Wood, DJ | 1 |
Yates, PJ | 1 |
Sindhu, KK | 1 |
Cohen, B | 1 |
Blood, T | 1 |
Gil, JA | 1 |
Owens, B | 1 |
Wan, YM | 1 |
Li, YH | 2 |
Wu, HM | 2 |
Xu, ZY | 1 |
Xu, Y | 2 |
Yang, LH | 2 |
Wu, XN | 1 |
Yang, JH | 1 |
Goel, R | 1 |
Fleischman, AN | 1 |
Tan, T | 1 |
Sterbis, E | 1 |
Huang, R | 2 |
Higuera, C | 1 |
Parvizi, J | 4 |
Rothman, RH | 2 |
Lakha, S | 1 |
Png, CYM | 1 |
Chun, K | 1 |
Ting, W | 1 |
Belcaro, G | 2 |
Cornelli, U | 2 |
Dugall, M | 2 |
Hosoi, M | 2 |
Cotellese, R | 2 |
Feragalli, B | 2 |
Phinney, TA | 1 |
Gibb, GJ | 1 |
Laghari, FJ | 1 |
Sobh, AH | 1 |
Koueiter, DM | 1 |
Mells, A | 1 |
Siljander, MP | 1 |
Karadsheh, MS | 1 |
Faour, M | 1 |
Piuzzi, NS | 1 |
Brigati, DP | 1 |
Klika, AK | 1 |
Mont, MA | 2 |
Barsoum, WK | 1 |
Higuera, CA | 1 |
Xu, W | 1 |
Zhang, T | 1 |
Yang, Z | 1 |
Nie, L | 1 |
Hu, S | 1 |
Ledda, A | 1 |
Corsi, M | 1 |
Ricci, A | 1 |
Ippolito, E | 1 |
Errichi, BM | 1 |
Cesarone, MR | 1 |
Bawa, H | 1 |
Weick, JW | 1 |
Dirschl, DR | 1 |
Luu, HH | 1 |
Peñaloza-Martínez, E | 1 |
Demelo-Rodríguez, P | 1 |
Proietti, M | 1 |
Soria Fernández-Llamazares, G | 1 |
Llamazares-Mendo, C | 1 |
Álvarez-Sala Walther, L | 1 |
Marra, AM | 1 |
Del Toro-Cervera, J | 1 |
Woon, CYL | 1 |
Shah, RR | 1 |
Pardi, BM | 1 |
Schwartz, BE | 1 |
Goldstein, JM | 1 |
Cipparrone, NE | 1 |
Goldstein, WM | 1 |
Runner, RP | 1 |
Gottschalk, MB | 1 |
Staley, CA | 1 |
Pour, AE | 1 |
Roberson, JR | 2 |
Bai, DS | 2 |
Xia, BL | 2 |
Zhang, C | 1 |
Ye, J | 1 |
Qian, JJ | 2 |
Jin, SJ | 2 |
Jiang, GQ | 2 |
Mihara, M | 1 |
Tamaki, Y | 1 |
Nakura, N | 1 |
Takayanagi, S | 1 |
Saito, A | 1 |
Ochiai, S | 1 |
Hirakawa, K | 1 |
Cohen, AT | 3 |
Bauersachs, R | 1 |
Mai, V | 1 |
Bertoletti, L | 1 |
Cucherat, M | 1 |
Jardel, S | 1 |
Grange, C | 1 |
Provencher, S | 1 |
Lega, JC | 1 |
Ghosh, A | 1 |
Best, AJ | 1 |
Rudge, SJ | 1 |
Chatterji, U | 1 |
Murasko, MJ | 1 |
Burk, DR | 1 |
Greenberg, B | 1 |
Neaton, JD | 1 |
Anker, SD | 1 |
Byra, WM | 1 |
Cleland, JGF | 1 |
Deng, H | 2 |
Fu, M | 1 |
La Police, DA | 1 |
Lam, CSP | 1 |
Mehra, MR | 1 |
Nessel, CC | 1 |
Spiro, TE | 1 |
van Veldhuisen, DJ | 1 |
Vanden Boom, CM | 1 |
Zannad, F | 1 |
Zou, P | 1 |
Li, H | 1 |
Cai, J | 1 |
Li, C | 1 |
Chen, Z | 1 |
Li, X | 1 |
Mirhosseini, SJ | 1 |
Forouzannia, SK | 1 |
Mostafavi Pour Manshadi, SM | 1 |
Ali-Hasan-Al-Saegh, S | 1 |
Naderi, N | 1 |
Sanatkar, M | 1 |
Netsch, C | 1 |
Stoehrer, M | 1 |
Brüning, M | 1 |
Gabuev, A | 1 |
Bach, T | 1 |
Herrmann, TR | 1 |
Gross, AJ | 1 |
Bagratuni, T | 1 |
Kastritis, E | 1 |
Politou, M | 1 |
Roussou, M | 1 |
Kostouros, E | 1 |
Gavriatopoulou, M | 1 |
Eleutherakis-Papaiakovou, E | 1 |
Kanelias, N | 1 |
Terpos, E | 1 |
Dimopoulos, MA | 1 |
Kulshrestha, V | 1 |
Kumar, S | 2 |
Raphael, IJ | 1 |
Tischler, EH | 1 |
Hozack, WJ | 2 |
Allen, G | 1 |
Ratkovic, M | 1 |
Basic-Jukic, N | 1 |
Gledovic, B | 1 |
Radunovic, D | 1 |
Prandoni, P | 2 |
Barbar, S | 1 |
Milan, M | 1 |
Vedovetto, V | 1 |
Pesavento, R | 1 |
Faustino, EV | 1 |
Hanson, S | 1 |
Spinella, PC | 1 |
Tucci, M | 1 |
O'Brien, SH | 1 |
Nunez, AR | 1 |
Yung, M | 1 |
Truemper, E | 1 |
Qin, L | 1 |
Li, S | 1 |
Marohn, K | 1 |
Randolph, AG | 1 |
Diez-Ewald, M | 1 |
Zou, Y | 1 |
Tian, S | 1 |
Sun, K | 1 |
Polkowski, GG | 1 |
Duncan, ST | 1 |
Bloemke, AD | 1 |
Schoenecker, PL | 1 |
Clohisy, JC | 2 |
Gist, KM | 1 |
Chima, RS | 1 |
Panos, GD | 1 |
Panos, LD | 1 |
Hafezi, F | 1 |
Gatzioufas, Z | 1 |
Tavil, B | 1 |
Kara, F | 1 |
Topaloglu, R | 1 |
Aytac, S | 1 |
Unal, S | 1 |
Kuskonmaz, B | 1 |
Cetin, M | 1 |
Besbas, N | 1 |
Gumruk, F | 1 |
Lawall, H | 1 |
Oberacker, R | 1 |
Zemmrich, C | 1 |
Bramlage, P | 1 |
Diehm, C | 1 |
Schellong, SM | 1 |
Cho, EH | 1 |
Ligh, C | 1 |
Hodulik, KL | 1 |
Hollenbeck, ST | 1 |
Stiefelhagen, P | 2 |
Aboyans, V | 1 |
Brodmann, M | 1 |
De Carlo, M | 1 |
Clement, D | 1 |
Mazzolai, L | 1 |
van Bortel, L | 1 |
van Sambeek, MR | 1 |
Vlachopoulos, C | 1 |
Schrör, K | 1 |
Pierce, TP | 1 |
Elmallah, RK | 1 |
Jauregui, JJ | 1 |
Cherian, JJ | 1 |
Oo, W | 1 |
Kozikowski, A | 1 |
Stein, J | 1 |
Lolis, J | 1 |
Pekmezaris, R | 1 |
Makaryus, AN | 1 |
Wolf-Klein, G | 1 |
Dimitrova, V | 1 |
Dimitrov, R | 1 |
Savov, A | 1 |
Hayek, S | 1 |
Batura, D | 1 |
Thompson, R | 1 |
Thachil, J | 1 |
Kaye, ID | 1 |
Patel, DN | 1 |
Strauss, EJ | 1 |
Alaia, MJ | 1 |
Garofolo, G | 1 |
Martinez, A | 1 |
Jazrawi, LM | 1 |
Braithwaite, I | 1 |
Dunbar, L | 1 |
Eathorne, A | 1 |
Weatherall, M | 1 |
Beasley, R | 1 |
Na, YG | 1 |
Fang, R | 1 |
Kim, YH | 1 |
Cho, KJ | 1 |
Kim, TK | 1 |
Nam, D | 2 |
Nunley, RM | 1 |
Johnson, SR | 1 |
Keeney, JA | 1 |
Barrack, RL | 2 |
Brill, JB | 1 |
Calvo, RY | 1 |
Wallace, JD | 1 |
Lewis, PR | 1 |
Bansal, V | 1 |
Sise, MJ | 1 |
Shackford, SR | 1 |
de Moreuil, C | 1 |
Ianotto, JC | 1 |
Eveillard, JR | 1 |
Carrier, M | 1 |
Delluc, A | 1 |
Verspohl, EJ | 1 |
Heller, S | 2 |
Secrist, E | 1 |
Shahi, A | 1 |
Chen, AF | 3 |
Tarantino, E | 1 |
Amadio, P | 1 |
Squellerio, I | 1 |
Porro, B | 1 |
Sandrini, L | 1 |
Turnu, L | 1 |
Cavalca, V | 1 |
Tremoli, E | 1 |
Barbieri, SS | 1 |
Chen, P | 1 |
Zuo, SQ | 1 |
Deirmengian, GK | 1 |
Smith, EB | 1 |
Maltenfort, M | 1 |
An, VV | 1 |
Phan, K | 1 |
Levy, YD | 1 |
Bruce, WJ | 1 |
Li, L | 2 |
Zhang, BJ | 1 |
Zhang, BK | 1 |
Ma, J | 1 |
Liu, XZ | 1 |
Jiang, SB | 1 |
Uno, Y | 1 |
Tsuboi, K | 1 |
Shimizu, M | 1 |
Tomosugi, T | 1 |
Shoka, M | 1 |
Hibino, S | 1 |
Matsushita, H | 1 |
Takahashi, T | 1 |
Okochi, O | 1 |
Kawase, Y | 1 |
Rebelo, J | 1 |
Nayan, S | 1 |
Choong, K | 1 |
Fulford, M | 1 |
Chan, A | 2 |
Sommer, DD | 1 |
Radzak, KN | 1 |
Wages, JJ | 1 |
Hall, KE | 1 |
Nakasone, CK | 1 |
Zhao, YT | 1 |
Tu, I | 1 |
Douketis, JD | 1 |
Schmidt-Braekling, T | 1 |
Pearle, AD | 1 |
Mayman, DJ | 1 |
Westrich, GH | 2 |
Waldstein, W | 1 |
Boettner, F | 1 |
Windecker, S | 1 |
Tijssen, J | 1 |
Giustino, G | 1 |
Guimarães, AH | 1 |
Mehran, R | 1 |
Valgimigli, M | 1 |
Vranckx, P | 1 |
Welsh, RC | 1 |
Baber, U | 1 |
van Es, GA | 1 |
Wildgoose, P | 1 |
Volkl, AA | 1 |
Zazula, A | 1 |
Thomitzek, K | 1 |
Hemmrich, M | 1 |
Dangas, GD | 1 |
Haynes, J | 1 |
Shaw, JA | 1 |
Yue-Meng, W | 1 |
Scheuerman, CM | 1 |
Gregg, JL | 1 |
Hussain, LR | 1 |
Feldstein, MJ | 1 |
Low, SL | 1 |
Woodward, LA | 1 |
Kwak, HS | 1 |
Cho, JH | 1 |
Kim, JT | 1 |
Yoo, JJ | 1 |
Kim, HJ | 1 |
Monagle, P | 1 |
Chalmers, E | 1 |
deVeber, G | 1 |
Kirkham, F | 1 |
Massicotte, P | 1 |
Michelson, AD | 1 |
Li, T | 1 |
Li, Q | 2 |
Sternin, IuI | 1 |
Safonov, LV | 1 |
Levando, VA | 1 |
Callaghan, JJ | 1 |
Warth, LC | 1 |
Hoballah, JJ | 1 |
Liu, SS | 1 |
Wells, CW | 1 |
Lowe, G | 1 |
Millar, JA | 1 |
Kakkos, SK | 1 |
Caprini, JA | 1 |
Geroulakos, G | 1 |
Nicolaides, AN | 1 |
Stansby, GP | 1 |
Reddy, DJ | 1 |
Ripert, T | 2 |
Menard, J | 2 |
Schoepen, Y | 2 |
N'guyen, P | 1 |
Rieu, P | 2 |
Brandt, B | 1 |
Staerman, F | 2 |
Raynal, G | 1 |
Blackhurst, H | 1 |
Gopal, SV | 1 |
Smith, I | 1 |
Malka, V | 1 |
Nicol, M | 1 |
Sun, Y | 1 |
Craig, N | 1 |
Wardlaw, D | 1 |
Tuthill, JI | 1 |
Khamashta, MA | 1 |
Salomon, O | 1 |
Dulitzky, M | 1 |
Apter, S | 1 |
Lieberman, JR | 2 |
Barnes, CL | 1 |
Lachiewicz, PF | 2 |
Hanssen, AD | 1 |
Clarke, HD | 1 |
Pellegrini, VD | 2 |
Obalum, DC | 1 |
Giwa, SO | 1 |
Adekoya-Cole, TO | 1 |
Ogo, CN | 1 |
Enweluzo, GO | 1 |
Bennett, P | 1 |
Nguyen, P | 1 |
Caldas, CA | 1 |
de Carvalho, JF | 1 |
Sárník, S | 1 |
Hofírek, I | 1 |
Hong, CH | 1 |
Napeñas, JJ | 1 |
Brennan, MT | 1 |
Furney, SL | 1 |
Lockhart, PB | 1 |
Shabana, M | 1 |
Shalaby, M | 1 |
Alhumayed, S | 1 |
Alshehri, A | 1 |
Sheth, NP | 1 |
Della Valle, CJ | 1 |
Scacciatella, P | 1 |
Butera, G | 1 |
Amato, G | 1 |
Tomassini, F | 1 |
Giorgi, M | 1 |
Marra, S | 1 |
Jacobs, AM | 1 |
Naroienejad, M | 1 |
Saedi, D | 1 |
Rezvani, A | 1 |
Mathias, JM | 1 |
Rivera Gorrin, M | 1 |
Donohoe, CL | 1 |
Sayana, MK | 1 |
Thakral, R | 1 |
Niall, DM | 1 |
Harsha, WJ | 1 |
Kau, RL | 1 |
Kim, N | 1 |
Hayden, RE | 1 |
Gukop, P | 1 |
Kakouros, N | 1 |
Hosseini, MT | 1 |
Valencia, O | 1 |
Kourliouros, A | 1 |
Sarsam, M | 1 |
Chandrasekaran, V | 1 |
Widmer, BJ | 1 |
Bassora, R | 1 |
Warrender, WJ | 1 |
Abboud, JA | 1 |
Larocca, A | 1 |
Cavallo, F | 1 |
Bringhen, S | 1 |
Di Raimondo, F | 1 |
Falanga, A | 1 |
Evangelista, A | 1 |
Cavalli, M | 1 |
Stanevsky, A | 1 |
Corradini, P | 1 |
Pezzatti, S | 1 |
Patriarca, F | 1 |
Cavo, M | 1 |
Peccatori, J | 1 |
Catalano, L | 1 |
Carella, AM | 1 |
Cafro, AM | 1 |
Siniscalchi, A | 1 |
Crippa, C | 1 |
Petrucci, MT | 1 |
Yehuda, DB | 1 |
Beggiato, E | 1 |
Di Toritto, TC | 1 |
Boccadoro, M | 1 |
Nagler, A | 1 |
Palumbo, A | 1 |
Raj, MD | 1 |
McDonald, C | 1 |
Brooks, AJ | 1 |
Drummond, M | 1 |
Lau, HM | 1 |
Patel, MI | 1 |
Bariol, SV | 1 |
Wang, AC | 1 |
Woo, HH | 1 |
Tang, WH | 1 |
Stitham, J | 1 |
Gleim, S | 1 |
Di Febbo, C | 1 |
Porreca, E | 1 |
Fava, C | 1 |
Tacconelli, S | 1 |
Capone, M | 1 |
Evangelista, V | 1 |
Levantesi, G | 1 |
Wen, L | 1 |
Martin, K | 1 |
Minuz, P | 1 |
Rade, J | 1 |
Patrignani, P | 1 |
Hwa, J | 1 |
Nunn, KP | 1 |
Bridgett, MR | 1 |
Walters, MR | 1 |
Walker, I | 1 |
Ramponi, F | 1 |
Wilson, MK | 1 |
Vedelago, J | 1 |
Bayfield, MS | 1 |
Broder, A | 1 |
Tobin, JN | 1 |
Putterman, C | 1 |
Gomes, AC | 1 |
Rubino, G | 1 |
Pinto, C | 1 |
Cipriano, A | 1 |
Furtado, E | 1 |
Gonçalves, I | 1 |
Hamilton, SC | 1 |
Whang, WW | 1 |
Anderson, BJ | 1 |
Bradbury, TL | 1 |
Erens, GA | 1 |
DeDea, L | 1 |
Becattini, C | 1 |
Agnelli, G | 1 |
Schenone, A | 1 |
Eichinger, S | 1 |
Bucherini, E | 1 |
Silingardi, M | 1 |
Bianchi, M | 1 |
Moia, M | 1 |
Ageno, W | 2 |
Vandelli, MR | 1 |
Grandone, E | 1 |
Vulcano, E | 1 |
Gesell, M | 1 |
Esposito, A | 1 |
Ma, Y | 1 |
Memtsoudis, SG | 1 |
Gonzalez Della Valle, A | 2 |
Patrono, C | 1 |
Rocca, B | 1 |
Zhang, HY | 1 |
Liu, H | 1 |
Yang, M | 1 |
Wei, SF | 1 |
Jonville-Béra, AP | 1 |
Bejan-Angoulvant, T | 1 |
Cossetto, DJ | 1 |
Goudar, A | 1 |
Parkinson, K | 1 |
Brotman, DJ | 1 |
Jaffer, A | 1 |
Alam, M | 1 |
Goldberg, LH | 1 |
Loke, YK | 1 |
Derry, S | 1 |
Elalamy, I | 1 |
Hatmi, M | 1 |
Sheikh, MA | 1 |
Topoulos, AP | 1 |
Deitcher, SR | 1 |
Ragucci, MV | 1 |
Leali, A | 1 |
Moroz, A | 1 |
Fetto, J | 1 |
Bath, PM | 2 |
Reitman, RD | 1 |
Emerson, RH | 1 |
Higgins, LL | 1 |
Tarbox, TR | 1 |
Keays, AC | 1 |
Mason, M | 1 |
Keays, SL | 1 |
Newcombe, PA | 1 |
Michaelides, M | 1 |
Aclimandos, W | 1 |
Hankey, GJ | 1 |
Eikelboom, JW | 1 |
Brenkel, IJ | 1 |
Cook, RE | 1 |
Breddin, HK | 1 |
Mantilla, CB | 1 |
Horlocker, TT | 1 |
Schroeder, DR | 1 |
Berry, DJ | 1 |
Brown, DL | 1 |
Kirwan, CC | 1 |
Nath, E | 1 |
Byrne, GJ | 1 |
McCollum, CN | 1 |
Peter, FW | 1 |
Steinau, HU | 1 |
Homann, HH | 1 |
Barker, JH | 1 |
Abraitis, V | 1 |
Mongirdiene, A | 1 |
Mockeviciene, A | 1 |
Oates-Whitehead, RM | 2 |
D'Angelo, A | 2 |
Mol, B | 2 |
Morimoto, S | 1 |
Nemoto, M | 1 |
Han, A | 1 |
Katoh, S | 1 |
Kurata, H | 1 |
Utsunomiya, K | 1 |
Tajima, N | 1 |
Kearon, C | 1 |
Samama, MM | 2 |
Dahl, OE | 1 |
Quinlan, DJ | 1 |
Mismetti, P | 1 |
Rosencher, N | 1 |
Weston, C | 1 |
Rao, U | 1 |
Shennib, H | 1 |
Endo, M | 1 |
Benhameid, O | 1 |
Majluf-Cruz, A | 1 |
Silva-Estrada, M | 1 |
Sánchez-Barboza, R | 1 |
Montiel-Manzano, G | 1 |
Treviño-Pérez, S | 1 |
Santoscoy-Gómez, M | 1 |
de Chávez-Ochoa, AR | 1 |
Corona-de la Peña, N | 1 |
Nieto-Cisneros, L | 1 |
Crotti, S | 1 |
Turpie, AG | 3 |
Neuman, Y | 1 |
Rukshin, V | 1 |
Tsang, V | 1 |
Atar, S | 1 |
Miyamoto, T | 1 |
Kobal, S | 1 |
Thompson, T | 1 |
Birnbaum, Y | 1 |
Horzewski, M | 1 |
Siegel, RJ | 1 |
Kaul, S | 1 |
Lapostolle, F | 1 |
Catineau, J | 1 |
Lapandry, C | 1 |
Adnet, F | 1 |
Farray, D | 1 |
Carman, TL | 1 |
Fernandez, BB | 1 |
Tan, KT | 1 |
Lip, GY | 1 |
Pokrovskiĭ, AV | 1 |
Dan, VN | 1 |
Sapelkin, SV | 1 |
Perisaev, GA | 1 |
Kharazov, AF | 1 |
Norris, TM | 1 |
Lacut, K | 1 |
Oger, E | 1 |
Le Gal, G | 1 |
Couturaud, F | 1 |
Louis, S | 1 |
Leroyer, C | 1 |
Mottier, D | 1 |
Kelly, J | 5 |
Rudd, A | 4 |
Lewis, RR | 4 |
Coshall, C | 2 |
Moody, A | 3 |
Hunt, BJ | 4 |
Geerts, WH | 1 |
Pineo, GF | 1 |
Heit, JA | 1 |
Bergqvist, D | 1 |
Lassen, MR | 1 |
Colwell, CW | 4 |
Ray, JG | 1 |
Cattaneo, M | 1 |
Hantler, C | 1 |
Despotis, GJ | 1 |
Sinha, R | 1 |
Chelly, JE | 1 |
Chen, HC | 1 |
Lai, JH | 1 |
Huang, GS | 1 |
Gao, HW | 1 |
Chen, CH | 1 |
Kuo, SY | 1 |
Chang, DM | 1 |
Rasmussen, HM | 1 |
Chauhan, PA | 1 |
Wille-Jørgensen, PA | 1 |
Parmar, K | 1 |
Kaboli, PJ | 1 |
Brenner, A | 1 |
Dunn, AS | 1 |
Anderson, DR | 1 |
McNaughton, H | 1 |
Barber, PA | 1 |
Gommans, J | 1 |
Nowitz, M | 1 |
Sick, PB | 1 |
Brosteanu, O | 1 |
Ulrich, M | 1 |
Thiele, H | 1 |
Niebauer, J | 1 |
Busch, I | 1 |
Schuler, G | 1 |
Kwong, LM | 1 |
Lotke, PA | 4 |
Lonner, JH | 3 |
Sarmiento, A | 3 |
Goswami, A | 1 |
Zee, RY | 2 |
Diehl, KA | 1 |
Ridker, PM | 3 |
Wolozinsky, M | 1 |
Yavin, YY | 1 |
Meyer Samama, M | 1 |
Baz, R | 1 |
Kottke-Marchant, K | 1 |
Srkalovic, G | 1 |
McGowan, B | 1 |
Yiannaki, E | 1 |
Karam, MA | 1 |
Faiman, B | 1 |
Jawde, RA | 1 |
Andresen, S | 1 |
Zeldis, J | 1 |
Hussein, MA | 2 |
Rajkumar, SV | 1 |
Hitos, K | 1 |
Fletcher, JP | 1 |
Salman, MC | 1 |
Ayhan, A | 1 |
Berend, KR | 1 |
Lombardi, AV | 1 |
Gelfer, Y | 1 |
Tavor, H | 1 |
Oron, A | 1 |
Peer, A | 1 |
Halperin, N | 1 |
Robinson, D | 1 |
Sharma, S | 1 |
Naru, T | 1 |
Khurshid, M | 1 |
Nazir, Z | 1 |
Nitsch, P | 1 |
Breuer, J | 1 |
Geipel, A | 1 |
Bartmann, P | 1 |
Gembruch, U | 1 |
Heep, A | 1 |
Heffline, MS | 1 |
Merli, GJ | 1 |
Hovens, MM | 1 |
Snoep, JD | 1 |
Tamsma, JT | 1 |
Huisman, MV | 1 |
Bottner, F | 1 |
Windsor, RE | 1 |
Laskin, RS | 1 |
Haas, SB | 1 |
Sculco, TP | 2 |
Grant, PJ | 1 |
Jaffer, AK | 1 |
Helft, G | 1 |
Gilard, M | 1 |
Le Feuvre, C | 1 |
Zaman, AG | 1 |
Patel, VP | 1 |
Walsh, M | 1 |
Sehgal, B | 1 |
Preston, C | 1 |
DeWal, H | 1 |
Di Cesare, PE | 1 |
Brenner, B | 2 |
Wu, QH | 1 |
Hirsh, J | 2 |
Maillardet, L | 1 |
Richter, ON | 1 |
Rath, W | 1 |
Alpagut, U | 1 |
Ugurlucan, M | 1 |
Dayioglu, E | 1 |
Dunkley, S | 1 |
Gaudry, L | 1 |
Jeong, GK | 1 |
Gruson, KI | 1 |
Egol, KA | 1 |
Aharonoff, GB | 1 |
Karp, AH | 1 |
Zuckerman, JD | 1 |
Koval, KJ | 1 |
Muntz, JE | 1 |
O'Connor, PJ | 1 |
Yin, H | 1 |
Vogenberg, FR | 1 |
Ashjian, P | 1 |
Chen, CM | 1 |
Pusic, A | 1 |
Disa, JJ | 1 |
Cordeiro, PG | 1 |
Mehrara, BJ | 1 |
Soileau, ES | 1 |
Sanchez, O | 1 |
Scappaticci, FA | 1 |
Skillings, JR | 1 |
Holden, SN | 1 |
Gerber, HP | 1 |
Miller, K | 1 |
Kabbinavar, F | 1 |
Bergsland, E | 1 |
Ngai, J | 1 |
Holmgren, E | 1 |
Wang, J | 1 |
Hurwitz, H | 1 |
Rossi, E | 1 |
Michelini, ME | 1 |
Pignatti, CB | 1 |
Zanotti, F | 1 |
Franchella, A | 1 |
Glynn, RJ | 2 |
Buring, JE | 2 |
Zimarino, M | 1 |
Renda, G | 1 |
De Caterina, R | 1 |
Beksaç, B | 1 |
Anderson, J | 1 |
Sharrock, NE | 1 |
Salvato, EA | 1 |
Ito, Y | 1 |
Mori, A | 1 |
Yonemura, K | 1 |
Hashimoto, Y | 1 |
Hirano, T | 1 |
Uchino, M | 1 |
Dorr, LD | 1 |
Gendelman, V | 1 |
Maheshwari, AV | 1 |
Boutary, M | 1 |
Wan, Z | 1 |
Long, WT | 1 |
Bellucci, S | 1 |
McBane, RD | 1 |
Leadley, RJ | 1 |
Baxi, SM | 1 |
Karnicki, K | 1 |
Wysokinski, W | 1 |
Katz, MG | 1 |
Shimonov, M | 1 |
Elias, S | 1 |
Ben Eli, M | 1 |
Hauptman, E | 1 |
Sasson, L | 1 |
Watson, HG | 1 |
Chee, YL | 1 |
Stechman, MJ | 1 |
Charlwood, N | 1 |
Gray, DW | 2 |
Handa, A | 1 |
Landolfi, R | 1 |
Di Gennaro, L | 1 |
Drouet, L | 1 |
Silbert, M | 1 |
Feng, D | 1 |
Zhang, K | 1 |
Jiang, X | 1 |
Leng, S | 1 |
Feng, J | 1 |
Sun, T | 1 |
Wu, L | 1 |
Zhou, C | 1 |
Iomhair, MM | 1 |
Lavelle, SM | 1 |
Goswami, AD | 1 |
Elwood, PC | 1 |
Hughes, C | 1 |
O'Brien, JR | 1 |
Buehler, KO | 1 |
D'Lima, DD | 2 |
Petersilge, WJ | 1 |
Walker, RH | 2 |
Beuhler, KO | 1 |
Otis, SM | 1 |
Pond, WW | 1 |
Cleland, J | 1 |
Julkunen, H | 1 |
Jouhikainen, T | 1 |
Kaaja, R | 1 |
Ferro, D | 1 |
Basili, S | 1 |
Roccaforte, S | 1 |
Di Franco, M | 1 |
Cipollone, F | 1 |
Ciabattoni, G | 1 |
Davì, G | 1 |
Morimoto, Y | 1 |
Sugimoto, T | 1 |
Okada, M | 1 |
Mukai, T | 1 |
Kennedy, JG | 1 |
Soffe, KE | 1 |
Rogers, BW | 1 |
Griffen, DR | 1 |
Dallo Vedova, PA | 1 |
Sullivan, RJ | 1 |
Sheehan, LJ | 1 |
Randi, ML | 1 |
Rossi, C | 1 |
Fabris, F | 1 |
Girolami, A | 1 |
Franke, A | 1 |
Hoffman, R | 1 |
Blumenfeld, Z | 1 |
Weiner, Z | 1 |
Younis, JS | 1 |
Frangos, SG | 1 |
Chen, AH | 1 |
Sumpio, B | 1 |
Freedman, KB | 2 |
Brookenthal, KR | 2 |
Fitzgerald, RH | 2 |
Williams, S | 1 |
Henley, E | 1 |
Cohen, A | 1 |
Quinlan, D | 1 |
Mahé, I | 1 |
Bergmann, JF | 1 |
Mahé, E | 1 |
Caulin, C | 1 |
Parker, M | 1 |
Thomas, DP | 2 |
Robertson, AJ | 1 |
Nargund, V | 1 |
Morris, PJ | 1 |
Lévesque, H | 1 |
Ginsberg, JS | 2 |
Greer, I | 1 |
Cairns, JA | 1 |
Théroux, P | 1 |
Lewis, HD | 1 |
Ezekowitz, M | 1 |
Meade, TW | 1 |
Waitkevicz, HJ | 1 |
Axelrod, D | 1 |
Lewis, R | 1 |
Sheu, JR | 1 |
Hsiao, G | 1 |
Lee, YM | 1 |
Yen, MH | 1 |
Sandercock, P | 1 |
Dennis, M | 1 |
Hien, P | 1 |
Morr, H | 1 |
Proctor, MC | 1 |
Greenfield, LJ | 1 |
Grace, DL | 1 |
Mesko, JW | 1 |
Brand, RA | 1 |
Iorio, R | 1 |
Gradisar, I | 1 |
Heekin, R | 1 |
Leighton, R | 1 |
Thornberry, R | 1 |
Lindenstrom, E | 1 |
Boysen, G | 1 |
De Deyn, P | 1 |
Friis, P | 1 |
Leys, D | 1 |
Marttila, R | 1 |
Olsson, J | 1 |
O'Neill, D | 1 |
Orgogozo, J | 1 |
Ringelstein, B | 1 |
van der Sande, J | 1 |
Collin, J | 1 |
Cleland, LG | 1 |
James, MJ | 1 |
Stamp, LK | 1 |
Penglis, PS | 1 |
Hollingsworth, SJ | 1 |
Dialysis, M | 1 |
Barker, SG | 1 |
Moyad, MA | 1 |
Tufano, A | 1 |
Cerbone, AM | 1 |
Di Minno, G | 1 |
Brunner, HI | 1 |
Chan, WS | 1 |
Feldman, BM | 1 |
Walker, N | 1 |
Rodgers, A | 1 |
Gray, H | 1 |
Little, JW | 1 |
Miller, CS | 1 |
Henry, RG | 1 |
McIntosh, BA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy[NCT04352439] | Phase 4 | 19 participants (Actual) | Interventional | 2020-08-08 | Completed | ||
Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Diseas[NCT01877915] | Phase 3 | 5,081 participants (Actual) | Interventional | 2013-09-10 | Completed | ||
A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes[NCT02556203] | Phase 3 | 1,653 participants (Actual) | Interventional | 2015-12-16 | Terminated (stopped due to Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator) | ||
Swelling Management After Total Knee Arthroplasty[NCT04841356] | 21 participants (Actual) | Interventional | 2021-04-01 | Completed | |||
Efficacy of Prolonged Distal Calf Compression as Part of a Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty: a Randomized Clinical Trial in 100 Patients[NCT02102828] | 100 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
Evaluation of Portal Venous System Thrombosis After Blunt Splenic Trauma Utilizing Doppler Ultrasound[NCT01906983] | 80 participants (Anticipated) | Observational [Patient Registry] | 2013-07-31 | Recruiting | |||
Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
Aspirin After Six Months or One Year of Oral Anticoagulants for the Prevention of Recurrent Venous Thromboembolism in Patients With Idiopathic Venous Thromboembolism. The WARFASA Study.[NCT00222677] | Phase 2/Phase 3 | 70 participants (Anticipated) | Interventional | 2004-05-31 | Active, not recruiting | ||
Prasugrel in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients[NCT04445623] | Phase 3 | 128 participants (Anticipated) | Interventional | 2020-07-31 | Not yet recruiting | ||
Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
Clinically-Important Venous Thromboembolism Following Lower Extremity Fractures: Epidemiology & Prevention[NCT00187408] | Phase 4 | 700 participants | Interventional | 2002-08-31 | Completed | ||
Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873] | Phase 2 | 35 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.) | ||
A Double Blind Randomized Control Trial of Post-Operative Low Molecular Weight Heparin Bridging Therapy Versus Placebo Bridging Therapy for Patients Who Are at High Risk for Arterial Thromboembolism (PERIOP 2)[NCT00432796] | Phase 3 | 1,473 participants (Actual) | Interventional | 2006-12-31 | Active, not recruiting | ||
Multiple Algorithms System Of All Scores in Embolism - MOSE[NCT02911012] | 15,208 participants (Anticipated) | Observational | 2016-10-31 | Recruiting | |||
Toronto Thromboprophylaxis Patient Safety Initiative (TOPPS): A Cluster Randomized Trial[NCT01869075] | 1,895 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
Multi-Screen Electronic Alert for Venous Thromboembolism Prevention[NCT00550082] | 880 participants (Actual) | Observational | 2007-07-31 | Completed | |||
The Protective Effect of Transcutaneous Electrical Acupoint Stimulation (TEAS) on Aged Patients Undergoing Lower Extremity Arthroplasty: A Single-Center, Double-Blinded, Randomised Controlled Trial[NCT02979028] | 300 participants (Anticipated) | Interventional | 2017-05-01 | Not yet recruiting | |||
Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
[NCT00000614] | Phase 3 | 0 participants | Interventional | 1998-09-30 | Completed | ||
The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery[NCT00733434] | Phase 4 | 242 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
A Multicenter, Open-Label, Phase III, Randomized, Active-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of rhuMAb VEGF (Bevacizumab), in Combination With Capecitabine Chemotherapy, in Subjects With Previously Treated Metastatic Bre[NCT00109239] | Phase 3 | 0 participants | Interventional | 2000-11-30 | Completed | ||
A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard Chemotherapy in Subjects With Metastatic Colorectal Cancer[NCT00109070] | Phase 3 | 0 participants | Interventional | 2000-09-30 | Completed | ||
A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab), a Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor, in Combination With 5-[NCT00109226] | Phase 2 | 0 participants | Interventional | 2000-08-31 | Completed | ||
Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women[NCT00000479] | Phase 3 | 39,876 participants (Actual) | Interventional | 1992-09-30 | Completed | ||
Influence of Tourniquet Use and Surgery Duration on the Incidence of Deep Vein Thrombosis in Total Knee Arthroplasty[NCT01559532] | 78 participants (Actual) | Observational | 2008-02-29 | Completed | |||
Effects on Bleeding in Knee Arthroplasty After Ischemic Preconditioning With Sevoflurane[NCT03379103] | 30 participants (Actual) | Interventional | 2018-02-02 | Completed | |||
Detection of Asymptomatic Venous Thrombosis in Gynecological Patients With Pelvic Masses[NCT03260270] | 60 participants (Anticipated) | Observational [Patient Registry] | 2017-09-30 | Not yet recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
(NCT04352439)
Timeframe: Up to six months
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 4 |
Adverse events will only include those that are determined to be related to the study drug. (NCT04352439)
Timeframe: Up to six months
Intervention | Participants (Count of Participants) |
---|---|
Aspirin | 0 |
Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 24.84 |
Placebo | 24.57 |
Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 13.44 |
Placebo | 14.27 |
Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 1.52 |
Placebo | 1.16 |
Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 9.46 |
Placebo | 9.96 |
Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 23.32 |
Placebo | 23.46 |
Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 2.04 |
Placebo | 1.21 |
Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 13.30 |
Placebo | 14.04 |
Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to Global treatment end date (approximately 54 months)
Intervention | Event rate per 100 patient-year (Number) |
---|---|
Rivaroxaban | 17.24 |
Placebo | 17.45 |
Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events. (NCT01877915)
Timeframe: Up to 227 Weeks
Intervention | Event rate per 100 patient-year (Number) | |
---|---|---|
Fatal Bleeding | Critical Space Bleeding with Permanent Disability | |
Placebo | 0.22 | 0.48 |
Rivaroxaban | 0.22 | 0.32 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
Intervention | Participants (Count of Participants) |
---|---|
VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
VTE Prophylaxis With Aspirin 81mg BID | 53 |
Composite of CV-death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism (per adjudication). (NCT02556203)
Timeframe: Through study completion, on average 16 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 83 |
Antiplatelet | 68 |
Composite of BARC 2,3 or 5 bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 148 |
Antiplatelet | 85 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 14 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 68 |
Antiplatelet | 63 |
Death or first adjudicated thromboembolic event (DTE), defined as composite of all-cause death, any stroke, myocardial infarction (MI), symptomatic valve thrombosis, pulmonary embolism (PE), deep vein thrombosis (DVT), and non-central nervous system (CNS) systemic embolism. (NCT02556203)
Timeframe: Through study completion, on average 16 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 105 |
Antiplatelet | 78 |
ISTH major bleeds (NCT02556203)
Timeframe: Through study completion, on average 16 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 49 |
Antiplatelet | 30 |
The net-clinical-benefit defined as the adjudicated composite of all-cause death, any stroke, myocardial infarction, symptomatic valve thrombosis, pulmonary embolism, deep vein thrombosis, non-CNS systemic embolism (efficacy); VARC life-threatening, disabling and VARC major bleeds (safety). (NCT02556203)
Timeframe: Through study completion, on average 16 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 137 |
Antiplatelet | 100 |
PBE is defined according to VARC (Valve Academic Research Consortium) definitions as the adjudicated composite of: Life-threatening, disabling or major bleeding. (NCT02556203)
Timeframe: Through study completion, on average 16 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 46 |
Antiplatelet | 31 |
Composite of TIMI major and minor bleedings (NCT02556203)
Timeframe: Through study completion, on average 16 months
Intervention | Participants (Count of Participants) |
---|---|
Rivaroxaban (Xarelto, BAY59-7939) | 42 |
Antiplatelet | 24 |
"Rates of appropriate VTE prophylaxis were determined as the number of patients who received VTE prophylaxis as a proportion of the number of patient at risk.~Rates reported are for the active phases (phase 1 and phase 2) and compare intervention to control.~Appropriate VTE prophylaxis was defined as:~in Hip Fracture Surgery - evidence-based VTE prophylaxis ordered within 24 of admission, restarted within 24 hours after surgery and continued for at least 10 days post-discharge in Major General Surgery - evidence-based VTE prophylaxis ordered within 24 hours post-surgery and continued for the duration of hospital stay in Acute Medical Illness - evidence-based VTE prophylaxis ordered within 24 hours of admission and continued for the duration of hospital stay.~Evidence-based VTE prophylaxis was determined to be according to the American College of Chest Physicians (ACCP) guidelines. The 9th version was the most current version at the time of the study." (NCT01869075)
Timeframe: End of study (end of phase 2) - measured over duration of hospital stay.
Intervention | percentage of patients (Number) |
---|---|
AMI - Knowledge Translation Toolkit | 64 |
AMI - Usual Care | 62 |
MGS - Knowledge Translation Toolkit | 67 |
MGS - Usual Care | 54 |
HFS - Knowledge Translation Toolkit | 85 |
HFS - Usual Care | 76 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
Intervention | participants (Number) |
---|---|
Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
Intervention | Participants (Number) | |
---|---|---|
Trough values outside normative range | Peak values outside normative range | |
Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
Intervention | participants (Number) | ||
---|---|---|---|
DVT | DVT after fondaparinux | PE | |
Fondaparinux Sodium | 2 | 1 | 0 |
No Fondaparinux | 2 | NA | 0 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic | 21 |
Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
Intervention | mL (Mean) |
---|---|
Tranexamic | 727.6 |
Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
Intervention | Participants (Count of Participants) |
---|---|
Tranexamic | 1 |
Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
Intervention | Units of packed red blood cells (Mean) |
---|---|
Tranexamic | 2.65 |
Placebo | 2.36 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
Intervention | participants (Number) | |
---|---|---|
Total invasive cancer | Cancer death | |
Aspirin + Vitamin E | 716 | 152 |
Aspirin Only | 722 | 132 |
Both Placebos | 706 | 143 |
Vitamin E Only | 721 | 156 |
(NCT00000479)
Timeframe: Average follow-up 10.1 years
Intervention | Participants (Number) | |||
---|---|---|---|---|
Major cardiovascular event | Stroke | Myocardial infarction | Cardiovascular death | |
Aspirin + Vitamin E | 232 | 108 | 102 | 54 |
Aspirin Only | 245 | 113 | 96 | 66 |
Both Placebos | 272 | 133 | 99 | 74 |
Vitamin E Only | 250 | 133 | 94 | 52 |
86 reviews available for aspirin and Deep Vein Thrombosis
Article | Year |
---|---|
What is the optimal management of thromboprophylaxis after liver transplantation regarding prevention of bleeding, hepatic artery, or portal vein thrombosis? A systematic review of the literature and expert panel recommendations.
Topics: Anticoagulants; Aspirin; Hemorrhage; Hepatic Artery; Humans; Liver Diseases; Liver Transplantation; | 2022 |
Comparison of non-criteria antiphospholipid syndrome with definite antiphospholipid syndrome: A systematic review.
Topics: Antiphospholipid Syndrome; Aspirin; Female; Humans; Pregnancy; Pregnancy Outcome; Thrombosis; Venous | 2022 |
The role of aspirin versus low-molecular-weight heparin for venous thromboembolism prophylaxis after total knee arthroplasty: a meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Heparin; Heparin, Low-Molecular-Weight; Hu | 2023 |
The efficacy and safety of aspirin in preventing venous thrombosis in major orthopedic surgery: An updated meta-analysis of randomized controlled trials.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Orthopedic Procedures; P | 2023 |
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.
Topics: Adult; Anticoagulants; Arthroscopy; Aspirin; Factor Xa Inhibitors; Hemorrhage; Heparin, Low-Molecula | 2020 |
Recent advances in understanding, diagnosing and treating venous thrombosis.
Topics: Anticoagulants; Aspirin; Humans; Venous Thromboembolism; Venous Thrombosis | 2020 |
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations.
Topics: Abortion, Habitual; Abortion, Spontaneous; Anticoagulants; Aspirin; Combined Modality Therapy; Femal | 2021 |
Comparison of Surgical Site Infection Risk Between Warfarin, LMWH, and Aspirin for Venous Thromboprophylaxis in TKA or THA: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Heparin, L | 2020 |
Low molecular weight heparin and aspirin for prevention of deep vein thrombosisafter orthopaedic surgery: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; Orthopedic Proc | 2021 |
Upper Extremity Deep Venous Thrombosis Prophylaxis After Elective Upper Extremity Surgery.
Topics: Aged; Aspirin; Cardiology; Comorbidity; Compression Bandages; Elective Surgical Procedures; Humans; | 2018 |
Update on extended treatment for venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; | 2018 |
Antithrombotic Agents.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Clinical Trials a | 2019 |
Rivaroxaban and the EINSTEIN clinical trial programme.
Topics: Adult; Aspirin; Child; Clinical Trials as Topic; Humans; Precision Medicine; Pulmonary Embolism; Riv | 2019 |
Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis.
Topics: Administration, Oral; Anticoagulants; Aspirin; Blood Coagulation; Female; Hemorrhage; Heparin, Low-M | 2019 |
Deep venous thrombosis and pulmonary embolism. Part 2--Prevention of recurrences: warfarin or low-molecular-weight heparin for at least 3 months.
Topics: Anticoagulants; Aspirin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inh | 2013 |
The risk of recurrent thromboembolic disorders in patients with unprovoked venous thromboembolism: new scenarios and opportunities.
Topics: Age Factors; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Dabigatran; Disease Management; | 2014 |
Role of platelet inhibition in microvascular surgery.
Topics: Angina, Unstable; Aspirin; Coronary Disease; Endothelium, Vascular; Free Tissue Flaps; Humans; Plate | 2014 |
The year in cardiology 2014: peripheral circulation.
Topics: Anticoagulants; Aortic Aneurysm, Abdominal; Aspirin; Biomarkers; Carotid Artery Diseases; Endovascul | 2015 |
[Aspirin and venous thromboses].
Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Trea | 2015 |
What's New in Venous Thromboembolic Prophylaxis Following Total Knee and Total Hip Arthroplasty? An Update.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Heparin; H | 2015 |
Aspirin as Thromboprophylaxis in Hip and Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemor | 2016 |
The 2016 American College of Chest Physicians treatment guidelines for venous thromboembolism: a review and critical appraisal.
Topics: Anticoagulants; Aspirin; Guidelines as Topic; Humans; Thoracic Surgery; Venous Thromboembolism; Veno | 2016 |
Rational thromboprophylaxis in medical inpatients: not quite there yet.
Topics: Anticoagulants; Aspirin; Australia; Clinical Trials as Topic; Cost-Benefit Analysis; Evidence-Based | 2008 |
Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thrombo-embolism in high-risk patients.
Topics: Aspirin; Clinical Trials as Topic; Fibrinolytic Agents; Humans; Intermittent Pneumatic Compression D | 2009 |
Thromboprophylaxis and obstetric management of the antiphospholipid syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Catastrophic Illness; Drug Therapy, Combi | 2009 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1. Flight deep vein thrombosis prophylaxis in lower limb injury.
Topics: Aerospace Medicine; Anticoagulants; Aspirin; Evidence-Based Medicine; Fractures, Bone; Heparin; Huma | 2009 |
Management of antiphospholipid syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolyt | 2009 |
Deep vein thrombosis: risk factors and prevention in surgical patients.
Topics: Anticoagulants; Aspirin; Awareness; Clinical Competence; Cyclooxygenase Inhibitors; Dextrans; Dihydr | 2009 |
DVT prophylaxis in total joint reconstruction.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2010 |
Economy class syndrome complicated by stroke: a rare condition due to paradoxical embolism--a case report and review of the literature.
Topics: Aircraft; Anticoagulants; Aspirin; Clopidogrel; Echocardiography; Embolism, Paradoxical; Foramen Ova | 2011 |
Perioperative management of the patient with rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Cervical Vertebrae; | 2010 |
Aspirin for lower limb arthroplasty thromboprophylaxis: review of international guidelines.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fondaparin | 2011 |
All I want for coagulation.
Topics: Aircraft; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Holidays; Humans; Practice Guidelin | 2011 |
Aspirin and Other COX-1 inhibitors.
Topics: Animals; Aspirin; Atherosclerosis; Atrial Fibrillation; Cyclooxygenase 1; Cyclooxygenase Inhibitors; | 2012 |
[What is the place of aspirin in venous thrombosis prophylaxis?].
Topics: Aspirin; Evidence-Based Medicine; Fibrinolytic Agents; Humans; Practice Guidelines as Topic; Pulmona | 2002 |
Thromboprophylaxis in patients undergoing total hip replacement.
Topics: Arthroplasty, Replacement, Hip; Aspirin; Bandages; Fibrinolytic Agents; Heparin, Low-Molecular-Weigh | 2003 |
[Factor V Leiden mutation and pregnancy complications].
Topics: Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; Factor V; Fem | 2003 |
Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery.
Topics: Anticoagulants; Aspirin; Female; Gynecologic Surgical Procedures; Heparin; Humans; Postoperative Com | 2003 |
Duration of venous thromboembolism prophylaxis after surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Drug Admin | 2003 |
Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool.
Topics: Adult; Aged; Aspirin; Blood Coagulation Factors; Blood Group Antigens; Ethnicity; Gonadal Steroid Ho | 2003 |
Antiplatelet drugs in cardiovascular diseases.
Topics: Aspirin; Atrial Fibrillation; Cardiovascular Diseases; Drug Resistance; Humans; Myocardial Infarctio | 2003 |
The safety of antithrombotic therapy during pregnancy.
Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Practic | 2004 |
The treatment and prevention of deep vein thrombosis in the preoperative management of patients who have neurologic diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Brain Diseases; Chondroitin Sulfat | 2004 |
Atrial fibrillation: should we target platelets or the coagulation pathway?
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk Assessment; | 2003 |
Thromboprophylaxis in medical patients: the role of low-molecular-weight heparin.
Topics: Administration, Oral; Anticoagulants; Aspirin; Cost-Benefit Analysis; Factor Xa Inhibitors; Heparin; | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Anticoagulants; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therap | 2004 |
Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance.
Topics: Aspirin; Clopidogrel; Drug Resistance; Humans; Ticlopidine; Treatment Failure; Treatment Outcome; Ve | 2004 |
Guidelines and alternatives for neuraxial anesthesia and venous thromboembolism prophylaxis in major orthopedic surgery.
Topics: Anesthesia, Conduction; Anesthesia, General; Aspirin; Factor Xa Inhibitors; Heparin; Humans; Orthope | 2004 |
Systemic lupus erythematosus with simultaneous onset of Kikuchi-Fujimoto's disease complicated with antiphospholipid antibody syndrome: a case report and review of the literature.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; An | 2005 |
Prevention of venous thromboembolism in medical and surgical patients.
Topics: Anticoagulants; Aspirin; Bandages; Chemoprevention; Early Ambulation; Hospitalization; Humans; Risk | 2005 |
Management problems of spontaneous ICH.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitalization; Humans; Magnetic Reso | 2005 |
Pharmacological prevention of venous thromboembolism in medical patients at risk.
Topics: Anticoagulants; Aspirin; Bandages; Clinical Trials as Topic; Heparin; Humans; Intermittent Pneumatic | 2005 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylami | 2005 |
[Patient with antithrombotic medication. Which do bleedings or preoperative?].
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atherosc | 2006 |
Multimodal venous thromboembolic disease prevention for patients undergoing primary or revision total joint arthroplasty: the role of aspirin.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Dose-Response Relationship | 2006 |
Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Embolism; Factor V; He | 2006 |
Prevention of thrombosis with warfarin, aspirin, and mechanical methods.
Topics: Anticoagulants; Aspirin; Bandages; Combined Modality Therapy; Heparin, Low-Molecular-Weight; Intermi | 2005 |
Aspirin in the prevention and treatment of venous thromboembolism.
Topics: Aspirin; Humans; Incidence; Secondary Prevention; Thromboembolism; Travel; Treatment Outcome; Venous | 2006 |
When should prophylactic anticoagulation begin after a hip fracture?
Topics: Anticoagulants; Aspirin; Chemoprevention; Heparin; Hip Fractures; Humans; Risk Assessment; Risk Fact | 2006 |
Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Admi | 2006 |
Travel-related thrombosis: is this a problem?
Topics: Aerospace Medicine; Aircraft; Anticoagulants; Aspirin; Chemoprevention; Heparin; Humans; Posture; Pr | 2006 |
[Application of anticoagulating medicine after surgery of cavity of pelvis and abdomen].
Topics: Abdomen; Anticoagulants; Aspirin; Heparin; Humans; Pelvis; Postoperative Complications; Venous Throm | 2006 |
Risk of thrombosis with lenalidomide and its prevention with aspirin.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Humans; Lenalidomide; Multiple Myeloma; Thalidomide; | 2007 |
[Thromboembolic diseases in pregnancy].
Topics: Algorithms; Anticoagulants; Aspirin; Contraindications; Coumarins; Female; Heparin; Heparin, Low-Mol | 2007 |
Major arterial involvement and review of Behcet's disease.
Topics: Adrenal Cortex Hormones; Adult; Aneurysm, False; Anticoagulants; Aortic Aneurysm, Abdominal; Arteria | 2007 |
WITHDRAWN: Anticoagulant and aspirin prophylaxis for preventing thromboembolism after major gynaecological surgery.
Topics: Anticoagulants; Aspirin; Female; Gynecologic Surgical Procedures; Heparin; Humans; Postoperative Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Com | 2007 |
Aspirin prophylaxis for thromboembolic disease after total joint arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement; Aspirin; Humans; Postoperative C | 2007 |
[Brief report: stroke in multiple myeloma patient treated with thalidomide].
Topics: Aged; Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Male; Multiple | 2007 |
[Vascular complications of essential thrombocythemia].
Topics: Age Factors; Aspirin; Case-Control Studies; Controlled Clinical Trials as Topic; Humans; Middle Aged | 2007 |
Aspirin and other antiplatelet drugs in the prevention of venous thromboembolism.
Topics: Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Venous Thromboembolism; | 2008 |
Platelets, aspirin, and cardiovascular disease.
Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Fibrinolytic Agents; Humans; Platelet Adhesivenes | 1998 |
Travelling with heart disease.
Topics: Alcohol Drinking; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Dehydration; Diet; Heart Diseas | 1998 |
[Phospholipid antigens, thrombosis and repeated fetal death].
Topics: Abortion, Habitual; Adult; Antigens; Aspirin; Biomarkers; Enzyme-Linked Immunosorbent Assay; Female; | 1996 |
Vascular drugs in the new millennium.
Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa | 2000 |
A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Confidence Intervals | 2000 |
Use of antithrombotic agents during pregnancy.
Topics: Aspirin; Female; Fetus; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregn | 2001 |
Antithrombotic agents in coronary artery disease.
Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Embolism; Fibrinolytic Agents; Humans; Platelet | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Male; | 2001 |
[Acetylsalicylic acid and bioptic methods in pneumology].
Topics: Aspirin; Biopsy; Bronchoscopy; Cardiovascular Diseases; Fiber Optic Technology; Humans; Lung; Venous | 2001 |
COX-2 inhibition and thrombotic tendency: a need for surveillance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Celecoxib; Cyclooxygenase I | 2001 |
Screening for subclinical deep-vein thrombosis.
Topics: Anticoagulants; Aspirin; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolytic Agents; He | 2001 |
An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2; Cycloox | 2001 |
[Advances and perspectives in the prevention of venous thromboembolic disease].
Topics: Anesthesia, Conduction; Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Myocardial I | 2001 |
The use of antithrombotic drugs in older people.
Topics: Aged; Aspirin; Clopidogrel; Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Myo | 2002 |
Antithrombotic agents: implications in dentistry.
Topics: Anticoagulants; Aspirin; Blood Coagulation Tests; Clopidogrel; Dental Care; Drug Interactions; Embol | 2002 |
34 trials available for aspirin and Deep Vein Thrombosis
Article | Year |
---|---|
Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban.
Topics: Acenocoumarol; Anticoagulants; Aspirin; Hemorrhage; Humans; Ischemic Stroke; Pilot Projects; Pulmona | 2023 |
Aspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture.
Topics: Adult; Anticoagulants; Aspirin; Chemoprevention; Extremities; Fractures, Bone; Hemorrhage; Heparin, | 2023 |
Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: A randomized clinical trial.
Topics: Aged; Aged, 80 and over; Aspirin; Female; Humans; Incidence; Laparoscopy; Liver Cirrhosis; Male; Mid | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.
Topics: Aged; Aspirin; Chronic Disease; Coronary Artery Disease; Death, Sudden; Disease Progression; Double- | 2019 |
Comparison of aspirin plus heparin with heparin alone on asymptomatic perioperative deep vein thrombosis in candidates for elective off-pump coronary artery bypass graft: a randomized clinical trial.
Topics: Aged; Anticoagulants; Aspirin; Coronary Artery Bypass, Off-Pump; Double-Blind Method; Drug Therapy, | 2013 |
DVT prophylaxis after TKA: routine anticoagulation vs risk screening approach - a randomized study.
Topics: Aged; Anticoagulants; Arthritis; Arthroplasty, Replacement, Knee; Aspirin; Chemoprevention; Female; | 2013 |
Administering aspirin, rivaroxaban and low-molecular-weight heparin to prevent deep venous thrombosis after total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-We | 2014 |
Prevention of Venous Thromboembolism after Arthroscopic Knee Surgery in a Low-Risk Population with the Use of Aspirin. A Randomized Trial.
Topics: Adolescent; Adult; Aged; Arthroscopy; Aspirin; Drug Administration Schedule; Female; Fibrinolytic Ag | 2015 |
Anticoagulation Therapy with Warfarin Versus Low-Dose Aspirin Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Azygos Vein; Female; Heparin, Low-Molecular-Weight | 2016 |
Prevention and Treatment of Lower Limb Deep Vein Thrombosis after Radiofrequency Catheter Ablation: Results of a Prospective active controlled Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Aspirin; Catheter Ablation; China; | 2016 |
Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study.
Topics: Aortic Valve Stenosis; Aspirin; Cardiovascular Diseases; Cause of Death; Clopidogrel; Drug Therapy, | 2017 |
Mobile pump deep vein thrombosis prophylaxis: just say no to drugs.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Arthroplasty, Replacement; Aspirin; Combined Modality | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Intermittent Pneumatic Compression D | 2017 |
A Comparison of Two Dosing Regimens of ASA Following Total Hip and Knee Arthroplasties.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clinical Protocols; | 2017 |
[Comprehensive prophylaxis for deep venous thrombosis after proximal femur fractures in geriatric patients].
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Combined Modality Therapy; Female; Femoral Neck Fr | 2008 |
Practice considerations of early aspirin administration following coronary artery bypass surgery.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Comorbidity; Coronary Artery Bypass; Drug-Re | 2011 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Aspirin for preventing the recurrence of venous thromboembolism.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hemorrhage; Humans; M | 2012 |
Comprehensive deep venous thrombosis prevention strategy after total-knee arthroplasty.
Topics: Aged; Anesthesia, Epidural; Arthroplasty, Replacement, Knee; Aspirin; Bandages; Early Ambulation; Fe | 2003 |
Risk factors for clinically relevant pulmonary embolism and deep venous thrombosis in patients undergoing primary hip or knee arthroplasty.
Topics: Aged; Anesthesia; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; A | 2003 |
Prospective randomized comparison of early and late results of a carbonized stent versus a high-grade stainless steel stent of identical design: the PREVENT Trial [corrected].
Topics: Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biocompatibl | 2005 |
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; C-Reactive Protein; Cardiova | 2006 |
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Aspirin; Dexamethasone; Doxorubicin; D | 2005 |
Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs low molecular weight heparin.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Female; | 2006 |
VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Spinal; Arthroplasty, Replacement, Knee; Aspirin; Combin | 2006 |
Mechanical calf compression and aspirin prophylaxis for total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Aspirin; Combined Modality Therapy; | 2007 |
Effects of random allocation to vitamin E supplementation on the occurrence of venous thromboembolism: report from the Women's Health Study.
Topics: 3' Untranslated Regions; Activated Protein C Resistance; Adult; Aspirin; Double-Blind Method; Drug A | 2007 |
Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial.
Topics: Aspirin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2007 |
Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus.
Topics: Adult; Antibodies, Antiphospholipid; Antigens; Aspirin; Cross-Sectional Studies; Dose-Response Relat | 1999 |
Deep vein thrombosis prophylaxis in hip fractures: a comparison of the arteriovenous impulse system and aspirin.
Topics: Aged; Aspirin; Cardiology; Female; Femoral Neck Fractures; Humans; Leg; Male; Platelet Aggregation I | 2000 |
Heparin thromboprophylaxis after acute stroke.
Topics: Acute Disease; Aged; Aspirin; Cause of Death; Cerebral Hemorrhage; Cerebral Infarction; Contraindica | 2001 |
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fib | 2001 |
"Long haul" flight and deep vein thrombosis: a model to help investigate the benefit of aspirin and below-knee compression stockings.
Topics: Adult; Aerospace Medicine; Aspirin; Bandages; Edema; Female; Humans; Leg; Male; Platelet Aggregation | 2001 |
196 other studies available for aspirin and Deep Vein Thrombosis
Article | Year |
---|---|
Combinatorial synthesis and biological evaluation of isoxazole-based libraries as antithrombotic agents.
Topics: Aldehydes; Animals; Bleeding Time; Combinatorial Chemistry Techniques; Databases, Factual; Drug Eval | 2002 |
Discovery of novel (6S/12aS)-heptachpyridone capable of inhibiting thrombosis in vivo.
Topics: Animals; Blood; Carbazoles; Diketopiperazines; Fibrinolytic Agents; Hydrolysis; Male; Rats, Sprague- | 2020 |
Both G protein-coupled and immunoreceptor tyrosine-based activation motif receptors mediate venous thrombosis in mice.
Topics: Animals; Aspirin; Blood Platelets; Clopidogrel; GTP-Binding Proteins; Immunoreceptor Tyrosine-Based | 2022 |
Early prevention and risk factors analysis of portal vein system thrombosis after laparoscopic splenectomy and pericardial devascularization.
Topics: Anticoagulants; Aspirin; Humans; Hypertension, Portal; Laparoscopy; Liver Cirrhosis; Portal Vein; Ri | 2022 |
Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures?
Topics: Anticoagulants; Aspirin; Chemoprevention; Enoxaparin; Hematoma; Heparin; Hip Fractures; Humans; Pelv | 2022 |
Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Humans; Incidence; Male; Medicare; | 2023 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Editorial Commentary: Prophylaxis Against Deep Venous Thrombosis Should Be the Norm After Knee Arthroscopy.
Topics: Anticoagulants; Arthroscopy; Aspirin; Humans; Pulmonary Embolism; Venous Thromboembolism; Venous Thr | 2022 |
Trends of Venous Thromboembolism After Total Hip Arthroplasty in the United States: Analysis From 2011 to 2019.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Fibrinolytic Agents; Humans; Postoperative | 2023 |
Aspirin Noninferior to Low-Molecular-Weight Heparin for Thromboprophylaxis After Fracture.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Venous Thromboembolism; Venous Throm | 2023 |
Does use of long-term aspirin impact outcomes in patients with acute pancreatitis?
Topics: Acute Disease; Acute Kidney Injury; Adult; Aged; Aspirin; Cysts; Humans; Incidence; Male; Medicare; | 2023 |
The impact of adopting low-molecular-weight heparin in place of aspirin as routine thromboprophylaxis for patients with hip fracture.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Postoperative Complic | 2023 |
Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Humans; Postoperative Complicat | 2023 |
Effect of low-dose aspirin administration on long-term survival of cirrhotic patients after splenectomy: A retrospective single-center study.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Follow-Up | 2019 |
Perioperative Management of Foot and Ankle Surgical Patients.
Topics: Ankle; Anticoagulants; Aspirin; Continuous Positive Airway Pressure; Exercise Therapy; Foot; Humans; | 2019 |
Postoperative aspirin use and its effect on bone healing in the treatment of ankle fractures.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Ankle Fractures; Anti-Inflammatory Agents, Non- | 2020 |
Incidence of venous thromboembolism after total hip, total knee and hip fracture surgery at Waitemata District Health Board following a peer-reviewed audit.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2020 |
A Rare Finding of Upper Limb Deep Venous Thrombosis in a Patient with COVID-19.
Topics: Anticoagulants; Arm; Aspirin; Betacoronavirus; Coronavirus Infections; COVID-19; Edema; Enoxaparin; | 2020 |
Efficacy and safety of aspirin and rivaroxaban for venous thromboembolism prophylaxis after total hip or knee arthroplasty: A protocol for meta-analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion; Hemorrhage; Humans; Met | 2020 |
Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report.
Topics: Aged; Angiogenesis Inhibitors; Aspirin; Colorectal Neoplasms; Coronary Artery Disease; Coronary Thro | 2021 |
Aspirin for Deep-Venous Thrombosis Prophylaxis After Anterior Cruciate Ligament Reconstruction.
Topics: Anterior Cruciate Ligament Reconstruction; Aspirin; Humans; Postoperative Complications; Retrospecti | 2021 |
Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Topics: Anticoagulants; Aspirin; Heparin; Humans; Multiple Myeloma; Retrospective Studies; Risk Factors; Ven | 2021 |
Outcomes of a single-center experience with classification and treatment of endothermal heat-induced thrombosis after endovenous ablation.
Topics: Anticoagulants; Aspirin; Catheter Ablation; Disease Progression; Endovascular Procedures; Female; Ho | 2017 |
Response to Letter to the Editor on "Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial".
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Bandages; Humans; Postoperative Complicati | 2017 |
Letter to the Editor on "Efficacy in Deep Vein Thrombosis Prevention With Extended Mechanical Compression Device Therapy and Prophylactic Aspirin Following Total Knee Arthroplasty: A Randomized Control Trial".
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Bandages; Humans; Postoperative Complicati | 2017 |
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; D | 2017 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
Association between aspirin use and deep venous thrombosis in mechanically ventilated ICU patients.
Topics: Adult; Aged; Aspirin; Female; Heparin; Humans; Intensive Care Units; Male; Middle Aged; Premedicatio | 2017 |
Wound Discharge After Pharmacological Thromboprophylaxis in Lower Limb Arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: An observational study (STROBE compliant).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Female; Humans; Leukocyte Coun | 2017 |
Venous thromboembolic prophylaxis after simultaneous bilateral total knee arthroplasty: aspirin
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Dose-Respo | 2018 |
Recurrent Iliofemoral Venous Thrombosis in the Setting of May-Thurner Syndrome as the Presenting Symptom of Behcet's Disease.
Topics: Aspirin; Behcet Syndrome; Endovascular Procedures; Factor Xa Inhibitors; Femoral Vein; Humans; Iliac | 2018 |
Long-haul flights, edema, and thrombotic events: prevention with stockings and Pycnogenol® supplementation (LONFLIT Registry Study).
Topics: Adult; Aircraft; Aspirin; Edema; Female; Flavonoids; Humans; Male; Middle Aged; Plant Extracts; Plat | 2018 |
CO poisoning as an associated risk factor for CVT.
Topics: Anticoagulants; Aspirin; Carbon Monoxide Poisoning; Female; Headache Disorders; Humans; Intracranial | 2018 |
The Role of Aspirin and Unfractionated Heparin Combination Therapy Immediately After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Bloo | 2018 |
Low-Dose Aspirin Is Safe and Effective for Venous Thromboembolism Prophylaxis Following Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Electronic Health Records; Female; H | 2018 |
Effect of different types of anticoagulants in the prevention of venous thrombosis in the operation of knee joint bone operation.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Female; Heparin, Low-Molecular-Weigh | 2018 |
Prevention of recurrent venous thrombosis and post-thrombotic syndrome.
Topics: Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Flavonoids; Glycosaminoglycans; Hum | 2018 |
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clin | 2018 |
Aspirin Alone Is Not Enough to Prevent Deep Venous Thrombosis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Chem | 2019 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Data | 2019 |
Clinical efficacy of risk-stratified prophylaxis with low-dose aspirin for the management of symptomatic venous thromboembolism after total hip arthroplasty.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthroplasty, Replacement, Hip; Aspirin; Female; Huma | 2020 |
Clinical Effectiveness of Aspirin as Multimodal Thromboprophylaxis in Primary Total Hip and Knee Arthroplasty: A Review of 6078 Cases.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2019 |
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; | 2020 |
The role of prophylactic use of low molecular weight heparin or aspirin in thromboembolic events in primary membranous nephropathy.
Topics: Adult; Aged; Aspirin; Beijing; Female; Glomerulonephritis, Membranous; Heparin, Low-Molecular-Weight | 2019 |
Safety and effectiveness of Thulium VapoEnucleation of the prostate (ThuVEP) in patients on anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Clopidogrel; Hemorrhage; Humans; Incidence; Mal | 2014 |
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
Topics: Acenocoumarol; Age Factors; Antineoplastic Agents; Aspirin; Female; Genetic Predisposition to Diseas | 2013 |
Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement; Aspirin; Female; Fibrinolytic Agents; Humans | 2014 |
Evidence appraisal of Cosetto DJ, Goudar A, Parkinson K. Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. J Orthop Surg (Hong Kong). 2012;20(3):341-343.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Male; Plat | 2013 |
Thrombosis of the great cerebral vein in a hemodialysis patient.
Topics: Adult; Aspirin; Cerebral Veins; Female; Fibrinolytic Agents; Humans; Intracranial Pressure; Kidney F | 2014 |
A multinational study of thromboprophylaxis practice in critically ill children.
Topics: Adolescent; Anticoagulants; Aspirin; Child; Child, Preschool; Critical Care; Critical Illness; Cross | 2014 |
[From apixaban to aspirin in the prevention of recurrent venous thromboembolism].
Topics: Anticoagulants; Antithrombins; Aspirin; Clinical Trials as Topic; Factor Xa Inhibitors; Heparin, Low | 2013 |
Aspirin's role in preventing recurring deep vein blood clots.
Topics: Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Risk Assessment; Secondary Prevention; Venous Thro | 2013 |
Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary?
Topics: Acetabulum; Adolescent; Adult; Age Factors; Aspirin; Female; Fibrinolytic Agents; Hip Dislocation, C | 2014 |
The landscape of thromboprophylaxis utilization in critically ill children: sparse and variable.
Topics: Anticoagulants; Aspirin; Critical Illness; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; M | 2014 |
Ischemic optic neuropathy after a long airplane flight: coincidence or rare economy class syndrome manifestation?
Topics: Aircraft; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diagnosis, Differential; Humans; Male; M | 2014 |
Case series of thromboembolic complications in childhood nephrotic syndrome: Hacettepe experience.
Topics: Adolescent; Age of Onset; Antithrombin III; Aspirin; Brain Infarction; Central Venous Catheters; Chi | 2015 |
Prevalence of deep vein thrombosis in acutely admitted ambulatory non-surgical intensive care unit patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; APACHE; Aspirin; Clopidogrel; Female; Fibrin Fibrinogen Deg | 2014 |
[What kind of thrombosis prevention for travel?].
Topics: Air Travel; Anticoagulants; Aspirin; Combined Modality Therapy; Exercise; Heparin, Low-Molecular-Wei | 2014 |
Antithrombotic Therapy Practices in Older Adults Residing in the Long-Term Care Setting.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Body Mass Index; Drug Therapy | 2015 |
[INDICATIONS FOR ANTITHROMBOTIC MEDICATION DURING PREGNANCY--ANALYSIS OF CURRENT PRACTICES IN BULGARIA].
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Bulgaria; Female; Heparin; Heparin, Low-Molecula | 2015 |
Prevention of deep vein thrombosis. First choice treatments.
Topics: Anticoagulants; Aspirin; Drug Therapy, Combination; Early Ambulation; Heparin, Low-Molecular-Weight; | 2015 |
Upper limb DVT after an optical urethrotomy in a patient with a permanent pacemaker: a case for continuing anticoagulation during low-risk urological surgery.
Topics: Aged; Aspirin; Humans; Male; Pacemaker, Artificial; Platelet Aggregation Inhibitors; Sick Sinus Synd | 2015 |
Duration of anticoagulation: the decision-making process.
Topics: Anticoagulants; Aspirin; Decision Making; Humans; Platelet Aggregation Inhibitors; Practice Guidelin | 2015 |
Venous thromboembolism rates in patients with lower limb immobilization after Achilles tendon injury are unchanged after the introduction of prophylactic aspirin: audit.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Anticoagulants; Aspirin; Drug Administration Schedule; Fem | 2016 |
Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Female; Fibrinolytic Age | 2015 |
The Effectiveness of a Risk Stratification Protocol for Thromboembolism Prophylaxis After Hip and Knee Arthroplasty.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspiri | 2016 |
Aspirin as added prophylaxis for deep vein thrombosis in trauma: A retrospective case-control study.
Topics: Anticoagulants; Aspirin; Case-Control Studies; Female; Humans; Leg; Male; Middle Aged; Prognosis; Re | 2016 |
[Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Heparin, Low-Molecular-Weight; Humans; Multiple Myel | 2016 |
[Acetylsalicylic acid-renaissance with venous thrombosis? ].
Topics: Aspirin; Humans; Platelet Aggregation Inhibitors; Postoperative Complications; Venous Thrombosis | 2016 |
Tranexamic Acid Can Be Administered to Arthroplasty Patients Who Receive Aspirin for Venous Thromboembolic Prophylaxis.
Topics: Aged; Antifibrinolytic Agents; Arthroplasty; Aspirin; Blood Loss, Surgical; Cohort Studies; Female; | 2016 |
Role of thromboxane-dependent platelet activation in venous thrombosis: Aspirin effects in mouse model.
Topics: Animals; Aspirin; Blood Platelets; Cell-Derived Microparticles; Disease Models, Animal; Male; Mice; | 2016 |
Aspirin Can Be Used as Prophylaxis for Prevention of Venous Thromboembolism After Revision Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Fema | 2016 |
[A Case of Portal Vein Thrombosis Occurring during CapeOX and Bevacizumab Combination Therapy for Liver Metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bevacizumab; Capecitabine; Humans; Li | 2016 |
To anticoagulate? Controversy in the management of thrombotic complications of head & neck infections.
Topics: Adolescent; Anticoagulants; Aspirin; Cavernous Sinus Thrombosis; Cerebral Angiography; Child; Child, | 2016 |
Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion | 2016 |
Acute pulmonary embolism with precordial T-wave inversion and negative D-dimer.
Topics: Aged; Angiography; Anticoagulants; Aspirin; Chest Pain; Diagnosis, Differential; Dyspnea; Electrocar | 2017 |
Aspirin, the Unsung Champion of Deep Venous Thrombosis Chemoprophylaxis: A Historical Perspective: Commentary on an article by Javad Parvizi, MD, FRCS, et al.: "Low-Dose Aspirin Is Effective Chemoprophylaxis Against Clinically Important Venous Thromboembo
Topics: Anticoagulants; Arthroplasty; Aspirin; Chemoprevention; Humans; Pulmonary Embolism; Thromboembolism; | 2017 |
Portal Vein Thrombosis in Patients With Cirrhosis Undergoing Elective Transjugular Intrahepatic Portosystemic Shunt: Risk Factors, Warfarin Efficacy, and Clinical Outcomes.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Elective Surgical Procedures; Female; Fibrosis | 2018 |
Intermittent Pneumatic Compression for the Prevention of Venous Thromboembolism after Total Hip Arthroplasty.
Topics: Adult; Age Factors; Aged; Arthroplasty, Replacement, Hip; Asian People; Aspirin; Computed Tomography | 2017 |
Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Child; Drug Therapy, Combination; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Human | 2008 |
[Systemic poly-enzyme therapy in prophylaxis of venous blood circulation disorder in the lower limbs in modern sport].
Topics: Adult; Ascorbic Acid; Aspirin; Drug Combinations; Drug Therapy, Combination; Humans; Hydrolases; Leg | 2008 |
Evaluation of deep venous thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty.
Topics: Arthroplasty, Replacement, Knee; Aspirin; Female; Humans; Male; Middle Aged; Postoperative Complicat | 2008 |
Thromboprophylaxis for patients at high risk of VTE.
Topics: Anticoagulants; Aspirin; Heparin; Hip Fractures; Humans; Practice Guidelines as Topic; Pulmonary Emb | 2008 |
[Anticoagulation after renal transplantation: a multicenter survey on clinical practice].
Topics: Adult; Anticoagulants; Aspirin; Female; France; Heparin; Humans; Kidney Transplantation; Male; Middl | 2009 |
[Lack of clinical evidence and variety of practice in the treatment of venous thrombosis in kidney transplants].
Topics: Anticoagulants; Aspirin; France; Heparin; Humans; Kidney Transplantation; Platelet Aggregation Inhib | 2009 |
Acute portal venous thrombosis after blunt abdominal trauma.
Topics: Abdominal Injuries; Accidents, Traffic; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; H | 2009 |
Incidence of thromboembolic complications in lumbar spinal surgery in 1,111 patients.
Topics: Anticoagulants; Aspirin; Female; Humans; Iatrogenic Disease; Incidence; Intermittent Pneumatic Compr | 2009 |
New observations in postpartum ovarian vein thrombosis: experience of single center.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Early Diagnosis; Enoxaparin; Female; Humans; Incid | 2010 |
Venous thromboembolism debate in joint arthroplasty.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Re | 2009 |
A comparison of methods used for the prevention of venous thromboembolic disease among orthopaedic surgeons at Wolverhampton, United Kingdom and Auckland, New Zealand.
Topics: Anticoagulants; Aspirin; Heparin, Low-Molecular-Weight; Humans; Intermittent Pneumatic Compression D | 2009 |
Preventing graft thrombosis after renal transplantation: a multicenter survey of clinical practice.
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; France; Health Surveys; Heparin; Humans; Intermittent | 2009 |
Primary antiphospholipid syndrome with and without Sneddon's syndrome.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Chloroquine; Female; Glucocorticoids; Hum | 2011 |
[Repeated local thrombolysis in a patient with axillary and subclavian vein injury and thrombosis].
Topics: Arm Injuries; Aspirin; Axillary Vein; Basketball; Female; Fibrinolytic Agents; Humans; Retreatment; | 2009 |
Frequency of bleeding following invasive dental procedures in patients on low-molecular-weight heparin therapy.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aspirin; Enoxaparin; Female; Gelat | 2010 |
Paediatric case report: primary antiphospholipid syndrome presented with non-thrombotic neurological picture psychosis; treat by antidepressants alone?
Topics: Antidepressive Agents; Antiphospholipid Syndrome; Antipsychotic Agents; Aspirin; Child; Female; Huma | 2009 |
Prevalence of central vein stenosis following catheterization in patients with end-stage renal disease.
Topics: Adult; Aged; Anticoagulants; Aspirin; Catheterization, Central Venous; Constriction, Pathologic; Cro | 2010 |
DVT prophylaxis: better living through chemistry: affirms.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Chemopreve | 2010 |
Steps to preventing DVT for outpatients.
Topics: Age Factors; Ambulatory Surgical Procedures; Anticoagulants; Aspirin; Humans; Outpatients; Postopera | 2010 |
Page kidney Doppler ultrasound.
Topics: Aspirin; Diagnosis, Differential; Diastole; Hematoma; Humans; Hypertension, Renal; Kidney Diseases; | 2011 |
Effects of antithrombogenic agents on microvenous anastomoses in a rat model.
Topics: Anastomosis, Surgical; Animals; Aspirin; Clopidogrel; Femoral Vein; Ketorolac Tromethamine; Microcir | 2011 |
Thromboembolic events are uncommon after open treatment of proximal humerus fractures using aspirin and compression devices.
Topics: Aspirin; Comorbidity; Early Ambulation; Female; Fracture Fixation, Internal; Humans; Incidence; Male | 2011 |
Stopping anticoagulation before TURP does not appear to increase perioperative cardiovascular complications.
Topics: Aged; Angina Pectoris; Anticoagulants; Arrhythmias, Cardiac; Aspirin; Blood Transfusion; Humans; Isc | 2011 |
Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane.
Topics: Adult; Aged; Aged, 80 and over; Aldehyde Reductase; Aspirin; Blood Glucose; Case-Control Studies; Co | 2011 |
Catastrophic pulmonary and paradoxical embolism.
Topics: Angiography; Aspirin; Cardiac Surgical Procedures; Critical Illness; Echocardiography, Transesophage | 2011 |
High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study.
Topics: Aged; Antibodies, Antiphospholipid; Aspirin; Biomarkers; Chronic Disease; Cross-Sectional Studies; E | 2012 |
Budd-Chiari syndrome in children and outcome after liver transplant.
Topics: Anticoagulants; Aspirin; Budd-Chiari Syndrome; Child, Preschool; Dipyridamole; Factor V; Female; Gas | 2012 |
Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Body Mass | 2012 |
DVT prophylaxis with aspirin in orthopedic surgery patients.
Topics: Aspirin; Humans; Orthopedic Procedures; Platelet Aggregation Inhibitors; Practice Guidelines as Topi | 2012 |
Aspirin for elective hip and knee arthroplasty: a multimodal thromboprophylaxis protocol.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement; Arthroplasty, Replacement, Hi | 2012 |
Antithrombotic activities of aqueous extract from Gardenia jasminoides and its main constituent.
Topics: Administration, Oral; Animals; Arteriovenous Shunt, Surgical; Aspirin; Carrageenan; Disease Models, | 2013 |
[Drugs news].
Topics: 4-Hydroxycoumarins; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroida | 2013 |
Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2012 |
'Coach class thrombosis': is the risk real? What do we tell our patients?
Topics: Aircraft; Aspirin; Bandages; Blood Viscosity; Contraindications; Heparin, Low-Molecular-Weight; Huma | 2002 |
Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy.
Topics: Aged; Anticoagulants; Aspirin; Carcinoma, Basal Cell; Clopidogrel; Drug Administration Schedule; Fem | 2002 |
Air travel and venous thrombosis: how much help might aspirin be?
Topics: Adult; Aircraft; Aspirin; Evidence-Based Medicine; Female; Humans; Male; MEDLINE; Middle Aged; Risk | 2002 |
Isolated internal jugular vein thrombosis: risk factors and natural history.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Female; Fibrinolytic Agents; | 2002 |
Atrial fibrillation, stroke, and acute antithrombotic therapy.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Randomized | 2003 |
A multimodality regimen for deep venous thrombosis prophylaxis in total knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Bandages; Chemoprevention; Combined Modality Therapy | 2003 |
The effect of anticoagulation on the restoration of range of motion after total knee arthroplasty: enoxaparin versus aspirin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Female; Fibrinolytic Age | 2003 |
Bilateral superior ophthalmic vein thrombosis in a young woman.
Topics: Adult; Aspirin; Eye; Factor VIII; Female; Fibrinolytic Agents; Humans; Risk Factors; Thrombophilia; | 2003 |
Antiplatelet drugs.
Topics: Aspirin; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein G | 2003 |
[Can acetylsalicylic acid be used for the treatment of venous diseases?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Platelet Aggregation Inhibitors; Pulmonary | 2003 |
Prophylaxis for venous thromboembolism during treatment for cancer: questionnaire survey.
Topics: Anticoagulants; Antineoplastic Agents; Aspirin; Bandages; Health Care Surveys; Heparin; Humans; Medi | 2003 |
Aspirin and microvascular surgery: an update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Microcirculation; Postoperative Complicati | 2003 |
["Economy class syndrome" associated with diabetes and Graves disease].
Topics: Aged; Aircraft; Anticoagulants; Aspirin; Diabetes Complications; Female; Graves Disease; Humans; Pul | 2003 |
A feasibility study of the safety and efficacy of a combined clopidogrel and aspirin regimen following off-pump coronary artery bypass grafting.
Topics: Anticoagulants; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Feasibility | 2003 |
Venous thrombosis among patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Activated Protein C Resistance; Adult; Aspirin; HIV Protease Inh | 2004 |
Augmentation of in-stent clot dissolution by low frequency ultrasound combined with aspirin and heparin. An ex-vivo canine shunt study.
Topics: Animals; Aspirin; Blood Vessel Prosthesis; Combined Modality Therapy; Dogs; Female; Heparin; Stents; | 2003 |
Venous thromboembolism in long-distance air travellers.
Topics: Aerospace Medicine; Aircraft; Aspirin; Bandages; Female; Humans; Male; Research Design; Risk Factors | 2004 |
[Aspirin versus oral anticoagulants following lower limb arterial reconstructions: what to choose?].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Drug Adminis | 2004 |
Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital-based case-control study.
Topics: Aged; Aspirin; Case-Control Studies; Clofibric Acid; Confidence Intervals; Female; Fibrinolytic Agen | 2004 |
Venous thromboembolism after acute ischemic stroke: a prospective study using magnetic resonance direct thrombus imaging.
Topics: Aged; Aspirin; Bandages; Female; Fibrinolytic Agents; Humans; Magnetic Resonance Imaging; Male; Pulm | 2004 |
[The use of thromboprophylaxis in Danish surgical departments. The results of the fifth survey].
Topics: Aspirin; Denmark; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Postoperative Complica | 2005 |
Screening for proximal deep vein thrombosis after acute ischemic stroke: a prospective study using clinical factors and plasma D-dimers.
Topics: Age Factors; Aged; Aspirin; Bandages; Female; Fibrin Fibrinogen Degradation Products; Humans; Ischem | 2004 |
Oral anticoagulation for the antiphospholipid antibody syndrome: can we now say less is more?
Topics: Administration, Oral; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspir | 2005 |
Deep vein thrombosis prophylaxis: better living through chemistry--in the affirmative.
Topics: Anticoagulants; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement | 2005 |
Deep venous thrombosis prophylaxis: better living through chemistry--in opposition.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Humans; Postoperative Complications; Pulmonary E | 2005 |
Thromboembolic disease prophylaxis in total hip arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Aspirin; California; Cause of Death; Evidence-Based Medicine; Exerci | 2005 |
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemo | 2005 |
Thalidomide therapy and deep venous thrombosis in multiple myeloma.
Topics: Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Immunosuppressive Agents; Multiple | 2005 |
Venous thromboembolism and fractured neck of femur.
Topics: Aged; Aged, 80 and over; Anesthesia; Anticoagulants; Aspirin; Blood Loss, Surgical; Blood Transfusio | 2005 |
Use of anti-thrombotic agents during chemotherapy for epithelial ovarian cancer.
Topics: Antineoplastic Agents; Aspirin; Drug Combinations; Female; Fibrinolytic Agents; Humans; Neoplasm Rec | 2006 |
Upper gastrointestinal bleeding after hip and knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplast | 2006 |
Maternal and fetal complications of antiphospholipid syndrome: a case report with long-term follow-up.
Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Follow-Up Stu | 2006 |
Dilatation of the abdominal umbilical vein is associated with increased risk of thrombotic complications.
Topics: Abdomen; Adult; Aspirin; Dilatation, Pathologic; Female; Fetal Diseases; Fibrinolytic Agents; Hepari | 2006 |
Preventing vascular complications after gastric bypass.
Topics: Adult; Aged; Anticoagulants; Aspirin; Bandages; Clinical Protocols; Drug Monitoring; Early Ambulatio | 2006 |
Thromboprophylaxis in orthopedic surgery.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2006 |
Factors associated with prolonged wound drainage after primary total hip and knee arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Body Mass Index; Dra | 2007 |
Aspirin in the prevention and treatment of venous thromboembolism: a rebuttal.
Topics: Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Pulmonary Embolism; Rese | 2007 |
Thalidomide causes platelet activation, which can be abrogated by aspirin.
Topics: Aspirin; Blood Platelets; Cell Aggregation; Humans; Monocytes; P-Selectin; Platelet Activation; Plat | 2007 |
Thromboprophylaxis after hip fracture: evaluation of 3 pharmacologic agents.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dextrans; Enoxaparin; Female; Fibrinolytic Agents; | 2007 |
Factors associated with thromboprophylaxis for orthopedic patients and their impact on outcome.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Huma | 2007 |
The effect of postoperative anticoagulation on microvascular thrombosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; | 2007 |
Would taking aspirin reduce the risk of developing blood clots in the legs during long plane flights?
Topics: Aircraft; Aspirin; Fibrinolytic Agents; Humans; Leg; Time Factors; Travel; Venous Thrombosis | 2007 |
[The risk of venous thromboembolism during air travel].
Topics: Aerospace Medicine; Aircraft; Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-W | 2007 |
A case of portal vein thrombosis after laparoscopy-assisted splenectomy and cholecystectomy in a child.
Topics: Anemia, Hemolytic, Congenital; Anticoagulants; Aspirin; Child; Cholecystectomy, Laparoscopic; Hepari | 2007 |
Triple antithrombotic therapy with aspirin, clopidogrel and warfarin--a persisting dilemma.
Topics: Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Thrombosis; Drug Therapy, Combination; Fibrinoly | 2007 |
Summaries for patients. Occurrence of venous thromboembolism in women taking low-dose aspirin.
Topics: Aspirin; Double-Blind Method; Drug Administration Schedule; Female; Fibrinolytic Agents; Follow-Up S | 2007 |
Symptomatic thromboembolism after one-stage bilateral THA with a multimodal prophylaxis protocol.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Clinical Protocols; Female; Humans; Inciden | 2007 |
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2007 |
Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs.
Topics: Administration, Oral; Angioplasty; Animals; Antithrombin III; Aspirin; Clopidogrel; Constriction, Pa | 2008 |
Portal vein thrombosis associated with coronary artery bypass surgery.
Topics: Aged; Aspirin; Bacteremia; Clopidogrel; Coagulase; Coronary Artery Bypass; Esophageal and Gastric Va | 2008 |
Administration of 75 mg of aspirin daily for 28 days is sufficient prophylaxis against renal transplant vein thrombosis.
Topics: Adult; Aged; Aspirin; Clinical Protocols; Drug Administration Schedule; Female; Fibrinolytic Agents; | 2007 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
[Prescription, monitoring of antithrombotic treatment: 1--antiplatelet agents].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Contraindica | 2007 |
Aspirin and air travellers.
Topics: Aerospace Medicine; Aspirin; Humans; Risk Factors; Venous Thrombosis | 2008 |
Comparison of anticoagulant effects on vein grafts between human TFPI gene transfection and aspirin oral administration.
Topics: Administration, Oral; Animals; Anticoagulants; Aspirin; Coronary Artery Bypass; Disease Models, Anim | 2008 |
DVT prophylaxis options: facts & fictions.
Topics: Arthroplasty, Replacement, Knee; Aspirin; Fibrinolytic Agents; Hemorrhage; Humans; Postoperative Com | 1998 |
Some effects of prophylactic aspirins and heparins on concurrent arterial and venous thrombosis in the same animal.
Topics: Animals; Aortic Diseases; Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Rats; Rats, S | 1998 |
Thromboembolic prophylaxis with use of aspirin, exercise, and graded elastic stockings or intermittent compression devices in patients managed with total hip arthroplasty.
Topics: Arthroplasty, Replacement, Hip; Aspirin; Bandages; Exercise Therapy; Female; Humans; Male; Platelet | 1999 |
Late deep venous thrombosis and delayed weightbearing after total hip arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Bandages; Cementation; Cohort Studies; Fema | 1999 |
Venous thromboembolic disease after hybrid hip arthroplasty with negative duplex screening.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Bandages; Female; | 1999 |
Venous thromboembolism associated with air travel.
Topics: Aerospace Medicine; Aspirin; Causality; Exercise; Humans; Incidence; Platelet Aggregation Inhibitors | 1999 |
Clinical assessment of vascular thrombosis using indium-111 platelet scintigraphy.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arteriosclerosis Obliterans; Aspirin; Blood Platelet | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
[Prevention of embolism in atrial septal defects?].
Topics: Adult; Age Factors; Anticoagulants; Aspirin; Coumarins; Embolism; Female; Fibrinolytic Agents; Heart | 2000 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Can low-dose aspirin prevent thromboembolic phenomena in patients undergoing surgery for hip fracture or elective arthroplasty?
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Cause of Death; Double-Blind Method; Follow-Up S | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Blood Transfusion; Cause of Death; Humans; Platelet Aggregation Inhibitors; Postoperative H | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hip Fractures; Humans; Meta-Analysis as | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aspirin; Hip Fractures; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Pulmonary | 2000 |
PEP trial. Pulmonary Embolism Prevention.
Topics: Aged; Arthroplasty, Replacement, Hip; Aspirin; Hip Fractures; Humans; Male; Myocardial Infarction; P | 2000 |
Thromboprophylaxis--which treatment for which patient?
Topics: Arthroplasty, Replacement, Hip; Aspirin; Chemoprevention; Fibrinolytic Agents; Hip Fractures; Humans | 2000 |
Low dose aspirin as prophylaxis against renal-vein thrombosis in renal-transplant recipients.
Topics: Adult; Aged; Aspirin; Cadaver; Cyclosporine; Databases as Topic; Drug Therapy, Combination; Fibrinol | 2000 |
[Aspirin and venous thromboembolism: some indications, but no certitude].
Topics: Aspirin; Fibrinolytic Agents; Humans; Thromboembolism; Venous Thrombosis | 2000 |
Hormone therapy and risk for venous thromboembolism: comments and correction.
Topics: Aspirin; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Platelet Aggrega | 2001 |
Antithrombotic effects of tetramethylpyrazine in in vivo experiments.
Topics: Acute Disease; Adenosine Diphosphate; Animals; Aspirin; Bleeding Time; Blood Pressure; Drug Evaluati | 2001 |
Venous thromboembolism after acute stroke.
Topics: Acute Disease; Aspirin; Bandages; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibit | 2001 |
Thromboprophylaxis in an academic medical center.
Topics: Academic Medical Centers; Age Factors; Aged; Aspirin; Bandages; Female; Heparin; Humans; Incidence; | 2001 |
Prophylactic low-dose aspirin therapy in patients having hip-fracture surgery or elective arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Hip Fractu | 2001 |
Venous thromboembolic disease management patterns in total hip arthroplasty and total knee arthroplasty patients: a survey of the AAHKS membership.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Bandages; | 2001 |
Deep-vein thrombosis in long-haul flights.
Topics: Anticoagulants; Aspirin; Bandages; Heparin, Low-Molecular-Weight; Humans; Thrombophlebitis; Travel; | 2001 |
Antithrombotic therapy.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Fibrinolytic Agents; Heparin; Humans; Throm | 2001 |
Early anticoagulation in acute ischaemic stroke.
Topics: Aspirin; Fibrinolytic Agents; Heparin; Humans; Stroke; Venous Thrombosis | 2002 |
Longterm anticoagulation is preferable for patients with antiphospholipid antibody syndrome. result of a decision analysis.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Decision Trees; Drug Therapy, Combination; Fibri | 2002 |
Changing patterns of pharmacological thromboprophylaxis use by orthopaedic surgeons in New Zealand.
Topics: Anticoagulants; Arthroplasty, Replacement; Aspirin; Drug Utilization; Elective Surgical Procedures; | 2002 |